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ABSTRACT
Causal inference methods including propensity score (PS) matching and weighting
have been widely used for comparative effectiveness research based on observational
clinical databases. There are new challenges of causal inference in medical stud-
ies, including how to handle clustered data structure, how to improve efficiency of
the traditional methods and etc. To overcome these challenges, we develop novel
causal inference method for estimating treatment effects. The proposed methods are
motivated by and applied to various studies of cardiovascular diseases and cardiac
surgeries.
In Chapter II, we aim to estimate causal treatment effect in clustered observa-
tional data and in our application clustered data structure arises from patients being
nested within hospitals. We propose a strategy to combine PS matching and outcome
regression model for estimating treatment effect while accounting for the hierarchical
nature of the data. We show that this method enjoys the double robustness property,
i.e. when either the PS or outcome model is correctly specified, the bias is negligible.
The proposed method has better performance than the usual PS method and the
existing doubly robust PS weighted method, and is more robust than the outcome
regression method.
Chapter III is motivated by comparing different types of ventricular assist devices
(VAD) for end-stage heart failure patients where patients are likely to receive a heart
transplant after receiving a VAD. We propose to treat heart transplants as depen-
dent censoring and propose an augmented inverse probability weighted method to
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estimate the treatment-specific difference in potential restricted mean lifetimes, had
no patients received heart transplant. Specifically, we first derive an estimator that
combines inverse probability of treatment weighting and inverse probability of censor-
ing weighting to account for the imbalance in baseline characteristics and censoring
that may depend on time-dependent confounders, respectively. Then we propose an
augmentation method to improve the efficiency of estimation. Large-sample prop-
erties of the proposed methods are studied and simulation studies are conducted to
assess the finite-sample performance.
In Chapter IV, we further extend and refine the work in Chapter III and develop
methods for estimating more meaningful causal treatment effects as opposed to the
average treatment effect. The goal is to overcome two potential problems related
to estimating the average treatment effect. Namely, depending on the specific ap-
plication the average treatment effect may not be the most clinical meaningful and
relevant quantity. Also it is known that estimators for average treatment effect often
have large variance even with the use of more sophisticated methods for improving
efficiency (e.g., augmentation). We propose augmented methods of matching weights
to estimate the treatment-specific difference in potential restricted mean lifetimes for
the matched population, had no patients received heart transplant. Simulation stud-





Observational data are widely used in health science research. In observational
data, the covariates are often unbalanced between treatment groups and need to be
adjusted when estimating causal treatment effect. Causal inference methods including
propensity score (PS) matching and weighting have been widely used for comparative
effectiveness research based on observational clinical databases. However, there are
new challenges of causal inference in health science research that cannot be well
handled by current methods, including how to handle clustered data structure, how to
improve efficiency of the traditional methods, how to define the clinically meaningful
estimand and etc. In this dissertation, to overcome these challenges, we develop novel
causal inference method for estimating treatment effects. The proposed methods are
motivated by and applied to studies of cardiovascular diseases and cardiac surgeries.
In Chapter II, we aim to estimate causal treatment effect in clustered observa-
tional data. In our application clustered data structure arises from patients being
nested within hospitals. Compared to cross-sectional data, the complexity of data
structure and treatment assignment mechanisms brings in additional challenges for
estimating causal effects. Regression modeling is a typical method to handle covariate
imbalance between treatment groups. By appropriately adjusting the confounding co-
variates, treatment effects can be consistently estimated from regression model. But
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the accuracy of estimation of causal effects highly relies on the correct specification of
outcome model, which is often difficult to achieve because the relationships between
outcome and covariates are complicated. Alternatively, PS matching is a popular one
in medical researches as it is intuitive and easy to implement. Instead of modeling
outcomes or specifying the heterogeneity of treatment effect, it aims to equalize the
covariate distributions between treatment groups. However, although PS matching
has a mature application procedure in cross-sectional data, it has not been well stud-
ied in clustered data. We propose a strategy to combine PS matching and outcome
regression model for estimating treatment effect while accounting for the hierarchical
nature of the data. We show that this method enjoys the double robustness property,
i.e. when either PS or outcome model is correctly specified, the bias is negligible.
The proposed method has better performance than the usual PS matching method
and the existing doubly robust PS weighted method, and is more robust than the
outcome regression method. We also study various types of matching strategies for
clustered data and compared their performances.
Chapter III is motivated by comparing different types of ventricular assist devices
(VAD) for end-stage heart failure patients where patients are likely to receive a heart
transplant after receiving a VAD. In this chapter, our aim is to estimate the causal
treatment effects but there are two challenges. First, as this is an observational s-
tudy, the distributions of patient baseline covariates are different between groups.
Second, patients may receive heart transplants after receiving VAD implantation. So
their survival outcomes we observed are due to not only VAD implantation but also
heart transplant. Also, we know that the patients with worse post-implant situa-
tion were more likely to need a heart transplant. To overcome these two challenges,
we treat heart transplant as dependent censoring and propose an augmented inverse
probability weighted method to estimate the treatment-specific difference in poten-
tial restricted mean lifetimes had no patients received heart transplant. Specifically,
2
we derive an estimator that combines inverse probability of treatment weighting and
inverse probability of censoring weighting to account for imbalance in baseline charac-
teristics and censoring that may depend on time-dependent confounders, respectively.
Then we propose an augmentation method to improve the efficiency of estimation.
Large-sample properties of the proposed methods are studied and simulation studies
are conducted to assess the finite-sample performance.
In Chapter IV, we further refine the work in Chapter III and develop methods
for estimating more meaningful causal treatment effects as opposed to the average
treatment effect. The goal is to overcome two potential problems related to estimat-
ing the average treatment effect. Namely, depending on the specific application the
average treatment effect may not be the most clinical meaningful and relevant quan-
tity. Also it is known that estimators for the average treatment effect (ATE) often
have large variance even with the use of more sophisticated methods for improving
efficiency (e.g., augmentation). In this chapter we focus on estimating the average
treatment effect on the matched population (ATM). In the application of Chapter
III, a small fraction (3.1%) of patients received BiVAD and the majority (96.9%) of
patients received LVAD. It is possible that the physicians only provide the option
of BiVAD implantation to the patients with more severe clinical conditions. In this
case, we think it may be more reasonable to estimate the treatment effect for the
patients who can receive either treatment. Hence, in this chapter we are interested in
estimating the treatment-specific difference in potential restricted mean lifetimes on
the matched population, had no patients received heart transplant. PS matching is a
common method for estimating the ATM, but it has drawbacks in practice, including
difficulty in estimating variance of PS matching estimator and developing methods to
improve efficiency. Li and Greene (2013) proposed a matching weight (MW) method
which is an analogue to one-to-one PS caliper matching method without replacement
and showed it is more efficient and has better variance estimation than the PS match-
3
ing. However, how to apply the MW method for causal inference for survival outcome
and further improve the efficiency remains unclear. In this chapter, motivated by the
same application with Chapter III, we adopt the matching weight method to esti-
mate the treatment-specific difference in potential restricted mean lifetimes had no
patients received heart transplant, had no patients received heart transplant. Then
we develop augmented methods to improve the efficiency.
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CHAPTER II
Doubly Robust Propensity Score Matching
Methods for Clustered Data
2.1 Introduction
In medical research, randomized design is gold standard of assessing causal treat-
ment effects. However, randomized trials are not always feasible due to high cost and
potential ethical issues. Alternatively, observational data are often used in medical
research. In observational studies, the covariates (e.g., age, gender, race, comorbid-
ity) are often unbalanced between treatment groups and need to be adjusted when
estimating causal treatment effects. Regression modeling is a typical method to han-
dle the covariate imbalance between treatment groups. By appropriately adjusting
the confounding covariates, treatment effects can be consistently estimated from re-
gression model. However, if differences in the characteristics across groups are large,
the causal effect estimated from regression models may be quite problematic because
valid estimations rely on model extrapolations which may be sensitive to model mis-
specification (Rubin, 1979). In other words, the accuracy of estimation of causal
effects highly relies on the correct specification of outcome models, which is often dif-
ficult to achieve because the relationships between outcome and covariates are often
complicated.
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Rosenbaum and Rubin (1983) proposed the propensity score (PS) methods to re-
duce bias in estimating causal effects. Instead of modeling outcomes or specifying
the heterogeneity of treatment effect, PS methods aim to equalize the covariate dis-
tributions between treatment groups. There are four types of PS methods (Austin,
2011), including matching (Rosenbaum and Rubin, 1985; Austin, 2008; Stuart , 2010),
inverse probability weighting (IPW) (Lunceford and Davidian, 2004), stratification
and covariate adjustment using propensity score (Rosenbaum and Rubin, 1984). A-
mong these methods, PS matching is popular in medical research as it is intuitive
and easy to implement. In last decades PS matching in cross-sectional data has been
well studied and improved in many aspects, including PS model fitting and matching
strategy (Rosenbaum, 1989; Gu and Rosenbaum, 1993; Stuart , 2010).
However, although PS matching has a mature application procedure in cross-
sectional data, it has not been well studied in clustered data, which is a common
type of medical data. In medical data patients are often nested in hospitals, and the
patient characteristics and treatment assignment mechanism may vary greatly among
hospitals. The complexity of data structure and treatment assignment mechanisms
introduces additional challenges for estimating causal effects using PS matching. In
the last decade, a few publications have explored PS matching in clustered data.
The performances of within-cluster and across-cluster matching have been compared
in the cases of different cluster sizes (Steiner et al., 2013; Kim and Steiner , 2015).
Single-level and two-level PS models together with new two-level matching strategies
have been studied (Thoemmes and West , 2011; Rickles and Seltzer , 2014; Arpino
and Cannas , 2016). Furthermore, to overcome the common problem of unobserved
cluster-level confounders when estimating causal treatment effects, Arpino and Mealli
(2011) and Oelrich (2014) developed PS matching methods, and Li et al. (2013)
and Yang (2016) developed inverse probability weighting methods, respectively. To
summarize, the previous researches have mainly focused on taking into account the
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hierarchy of data structure by using multi-level PS models or improving matching
strategies, or solving the problem of unobserved cluster-level confounders.
Medical researchers often perform PS matching and estimate treatment effects
by calculating the difference of the average of observed outcomes between treatment
groups. Unpaired or paired two-sample tests are used to assess the significance of the
estimated treatment effects. However, generally PS matching cannot remove all the
imbalances between groups. Directly comparing the average outcome between group-
s after matching precludes further removing residual imbalances and improving the
efficiency. It has been suggested that post-matching outcome regression may further
remove the residual imbalances in matched data and thus improve the performance
of PS matching (Rubin, 1973, 1979; Rubin and Thomas , 2000; Ho et al., 2007; Stu-
art , 2010). However, to our knowledge, no study has evaluated the performance of
combining PS matching and outcome regression using simulation study, especially for
clustered data.
This chapter is motivated by a multi-center observational cardiac study. The pa-
tient data were collected from multiple hospitals with widely varying sizes, and two
treatment groups were unbalanced in patient-, surgeon- and hospital-level character-
istics. The aim of the study is to estimate the causal effect of cardiac treatment.
In this chapter, we propose a strategy to combine PS matching and outcome regres-
sion, while accounting for the hierarchical nature of the data. We also study different
matching methods in clustered data and compare the performances. The remainder
of the chapter is organized as follows: we propose the methods in Section 2.2; Section




2.2.1 Assumptions for Causal Inference in Two-level Data
Without loss of generality, we consider a two-level data structure, including hospital
and patient levels. Considering a two-level observational data structure where n
patients are nested into m hospitals, i.e. n =
∑m
i=1 ni, i = 1, ...,m, where ni denotes
number of patients in hospital i. Let Zij indicate whether patient j in hospital i
is assigned to treatment (Zij = 1) or control (Zij = 0). Let X denote the vector
of patient-level covariates, V denote the vector of hospital-level covariates, and Y
denote the continuous outcome. The propensity score eij is defined as the probability
of being assigned to treatment for patient j in hospital i, conditional on patient-
and/or hospital-level covariates, i.e. eij = Pr(Zij = 1|Xij, Vi).
To estimate the causal treatment effect, we adopt the potential outcome frame-
work. Unlike cross-sectional data, in two-level data analysis, the framework need
to be adjusted to account for the hierarchical nature of data and the existence of
hospital-level covariates. We assume patient j in hospital i has two potential out-
comes Y 1ij and Y
0
ij , which denote the hypothetical outcomes if the patient has taken
treatment (Zij = 1) or control (Zij = 0) in his/her observed hospital, respectively.
There are two common estimands including the average treatment effect (ATE) and
the average treatment effect on the treated (ATT). In this chapter we are interest-
ed in estimating the ATE, i.e. E(Y 1ij − Y 0ij). Valid estimation of the ATE depends
on three assumptions. We first make the stable unit treatment value assumption
(SUTVA), stating that the potential outcomes for one patient are not affected by the
treatment assignment of other patients in either the same or different hospitals, i.e.
Yij = ZijY
1
ij + (1 − Zij)Y 0ij . The second assumption is unconfoundedness, claiming
that
(Y 1ij , Y
0
ij) ⊥ Zij|Xij, Vi or (Y 1ij , Y 0ij) ⊥ Zij|(Xij, hospital i). (2.1)
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The symbol “⊥” denotes independence. Rosenbaum and Rubin (1983) proved that for
cross-sectional data, if the unconfoundedness assumption i.e. (Y 1, Y 0) ⊥ Z|X hold-
s, the potential outcomes are independent of treatment assignment conditional on
propensity score i.e. (Y 1, Y 0) ⊥ Z|e(X), which is the theory basis for the PS match-
ing methods. Here, we modify the unconfoundedness assumption for the two-level
data setting. Specifically, we assume that the potential outcomes for one patient are
independent of treatment assignment conditional on both patient- and hospital-level
covariates, or conditional on patient-level covariates and hospital membership. The
second part of Equation (2.1) applies to matching within hospital. Matching within
hospital does not require observing hospital-level covariates, because the hospital-level
covariates are automatically balanced as the matched pairs are in the same hospital.
In this case, the hospital membership is sufficient for making valid estimation of the
ATE, which has also been claimed by Thoemmes and West (2011) and Steiner et al.
(2013). Based on the second part of Equation (2.1), matching within hospital is a
method to make valid inference in the presence of unobserved cluster-level covariates.
The third assumption is the overlap assumption, which states the patients in each
hospital have positive probabilities of being assigned to either the treatment or the
control, i.e.
0 < eij < 1. (2.2)
Rosenbaum and Rubin (1983) considered it as “strong ignorable” if both unconfound-
edness and overlap assumptions are satisfied.
2.2.2 Propensity Score Models
The propensity scores are often not observed and need to be estimated from models
(e.g. logistic model). Depending on how to model the hierarchical effect of hospitals,
we consider three types of PS models. The first one is single-level logistic model, for
which we ignore the hierarchical data structure and model the probability of being
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assigned to treatment using patient-level covariates, i.e.
Single-level PS model: logit{P (Zij = 1|Xij)} = Xijβ.
As two-level PS models have been shown to reduce bias of causal treatment effects
in clustered data (Arpino and Mealli , 2011; Li et al., 2013), we consider two types
of two-level PS models: the random-effect logistic model and the fixed-effect logistic
model, i.e.
Random-effect PS model: logit{P (Zij = 1|Xij, Vi)} = bi +Xijβ + Viγ,
where bi is a random intercept for hospital i.
Fixed-effect PS model: logit{P (Zij = 1|Xij, Vi)} = Hi +Xijβ,
where Hi is the indicator for hospital i.
It is important to include all covariates related to treatment assignment into the
PS model. If it is not clear that which characteristics are associated with treatment
assignment mechanisms, it has been recommended to include as many covariates as
possible to avoid potential confounding (Stuart , 2010), although the trade-off is a
slight inflation of variance of the estimator (Brookhart et al., 2006).
2.2.3 Matching
After estimating PS from models, the next step is to match patients between
groups using estimated PS. In cross-sectional data analysis, various matching strate-
gies have been proposed and studied, including nearest neighbor matching, optimal
matching and nearest neighbor matching within a caliper (caliper matching). The
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caliper matching is a popular method in medical research and has been shown to
be less biased than nearest neighbor matching and optimal matching (Austin, 2014).
Gu and Rosenbaum (1993) have shown that optimal matching does not improve the
performance of balancing between groups compared to other matching algorithms,
although it performs better at minimizing the within pair difference. In this chap-
ter, the primary interest is to estimate the ATE instead of achieving best individual
matching pair, so we use the caliper matching with caliper equal to 0.10 standard
deviation of the estimated propensity score. Let us take the caliper matching within
hospital as an example; let Mij be the matched set for patient j in hospital i who
received treatment, Si0 be the set of all control patients in hospital i, j
′ be the patient
id in Si0. Then Mij can be formally expressed as
Mij =
{
j′ ∈ Si0 : min
j′∈Si0
|êij − êij′| ≤ 0.10σ̂e
}
.
With regards to matching with or without replacement, we consider three methods,
including matching without replacement, matching with replacement, and modified
matching with replacement. Matching without replacement is frequently used in
medical research. It means that one patient can only be matched once and after
s/he is matched, s/he would not be considered in future matching. Matching with
replacement means that the patients are allowed to match with multiple patients.
It has been argued that matching with replacement may decrease bias but cause
more complicated inference due to the violation of independence assumption (Stuart ,
2010). For matching with replacement, Dehejia and Wahba (1999) and Hill et al.
(2004) proposed to incorporate weights into outcome analysis. For example, if 1
control is matched to 5 treated patients, then each of these 5 patients receive a
weight of 1/5. Beside these two traditional methods, we propose a third way that we
call “modified matching with replacement”. Specifically, we first match the patients
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without replacement, then for the unmatched patients, we attempt to match them
with the patients that have already been matched. When an unmatched patient can
be matched to multiple patients, we match her/him to the patient with fewest times
being matched.
A new challenge for PS matching in clustered data is how to handle the hierarchical
data structure during matching. Generally there are two common matching methods,
including within-hospital matching and across-hospital matching. Within-hospital
matching only matches the patients in the same hospital. It achieves perfect hospital-
level balance between groups, but the matching rates may be low, especially when
hospital sizes are small. Across-hospital matching ignores the hierarchical structure
and matches patients regardless of whether they are in the same hospital, which has
been shown to perform better for reducing bias. In this chapter, we consider both
within-hospital and across-hospital matching, and also propose a matching method
called “modified across-hospital matching”, that is, we first match patients within
the same hospital, and for the patients who cannot be matched within hospital, we
match them across hospitals. This is similar to the preferential matching proposed
by Arpino and Cannas (2016).
2.2.4 Post-matching Analysis
Traditionally people perform PS matching and then estimate the ATE or ATT by
calculating the difference in average outcomes between two matched groups. Unpaired
or paired two-sample tests are used to assess the significance. As stated in Section
2.1, it has been suggested that post-matching covariate adjustment would potentially
improve the estimation. Hence, instead of directly comparing the averages between
two matched groups, we propose a method of modeling outcome using covariates
after matching. Similar to PS models, we consider three types of outcome models
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depending on how to account for hierarchical effects of hospitals:
Single-level outcome model: Yij ∼ Zijβ +Xijγ (2.3)
Random-effect outcome model: Yij ∼ αi + Zijβ +Xijγ + Viθ (2.4)
Fixed-effect outcome model: Yij ∼ Hi + Zijβ +Xijγ, (2.5)
where αi is a random intercept for hospital i, and Hi is the indicator for hospital i.
There are still debates on whether to account for matching pairs in the post-
matching analysis (Rubin, 1973; Hill and Reiter , 2006; Schafer and Kang , 2008; S-
tuart , 2008); we have chosen not to account for matching pairs in this chapter. In
the situation that we do not observe all the hospital-level confounders, the random-
effect PS model will be biased due to the endogeneity problem (Mundlak , 1978). In
this case, the fixed-effect model is still unbiased because the effect of the missing
hospital-level covariates would be absorbed into hospital indicator Hi in Model (2.5).
2.3 Simulation Study
We perform a simulation study to evaluate the performance of the proposed meth-
ods using 1000 Monte Carlo datasets. The number of hospitals is 30. We consider
three scenarios by varying hospital sizes. The hospital sizes in three scenarios are 30,
100 and a random number generated from the uniform distribution (30,170), respec-
tively.
Let Xij denote the patient-level covariate vector and Xij = (X1,ij, X2,ij, X3,ij)
T .
X1,ij and X3,ij are generated from standard normal distribution N(0, 1). X2,ij is gen-
erated from Bernoulli(0.6). The hospital-level covariate Vi is simulated from N(0, 1).
The treatment indicator Zij is generated from the Bernoulli distribution with param-
eter expit(X1,ij +X2,ij +0.5Vi+ηi), where ηi ∼ N(0, 1). The outcome Yij is generated
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from a two-level random-effect model:
Yij = αi + 1.5X1,ij +X
2
1,ij + 2.5X2,ij + 1.5X3,ij + 3Zij + Vi + εij,
where αi ∼ N(0, 1.2), εi,j ∼ N(0, 2).
To estimate propensity scores, we consider five PS models: (1) the benchmark
model, (2) the single-level model with linear forms of all patient-level covariates, (3)
the single-level model with linear forms of all patient-level covariates except X1,ij, (4)
the random-effect model with linear forms of all patient-level covariates, and (5) the
fixed-effect model with linear forms of all patient-level covariates. For the PS Models
(2)-(5), we omit hospital-level covariate in order to mimic the realistic situation that
we do not observe hospital-level confounders.
PS model 1 (benchmark): logit(eij) = bi +X1,ij +X2,ij + Vi
PS model 2: logit(eij) = X1,ij +X2,ij +X3,ij
PS model 3: logit(eij) = X2,ij +X3,ij
PS model 4: logit(eij) = bi +X1,ij +X2,ij +X3,ij
PS model 5: logit(eij) = Hi +X1,ij +X2,ij +X3,ij.
After estimating propensity scores, we consider three ways to match patients as de-
scribed in Section 2.2: within-hospital, across-hospital and modified across-hospital
matching. Regarding matching with or without replacement, we also consider three
ways: with replacement, without replacement and modified with replacement match-
ing. After matching, we further perform outcome regression modeling using five
models, including (1) benchmark model, (2) single-level model with Zi as the only
covariate, (3) mixed-effect model with Zi as the only covariate, (4) random-effect
model with Zi and linear forms of all patient-level covariates, and (5) fixed-effect
model with Zi and linear forms of all patient-level covariates. For outcome model
(2)-(5), we omit hospital-level covariate Vi.
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Outcome model 1 (benchmark): Yij ∼ bi+Zij+X1,ij+X21,ij+X2,ij+X3,ij+Vi
Outcome model 2: Yij ∼ Zij
Outcome model 3: Yij ∼ bi + Zij
Outcome model 4: Yij ∼ bi + Zij +X1,ij +X2,ij +X3,ij
Outcome model 5: Yij ∼ Hi + Zij +X1,ij +X2,ij +X3,ij.
In each scenario, in addition to the proposed methods, we also evaluate the outcome
regression method, PS matching method and Li’s doubly robust weighting methods,
in terms of bias and Monte Carlo standard deviation. We estimate the standard error
via the bootstrap approach. In each scenario, we mainly focus on matching without
replacement; the detailed simulation results of the matching with replacement and
the modified matching with replacement can be found in Appendix A.1 and A.2.
Tables 2.1-2.6 show the simulation results for matching without replacement in
three scenarios. We first describe the simulation results for Scenario 1 (Table 2.1 and
2.2) from the following six aspects.
First, we show that the proposed method has the double robustness property.
Double robustness means that when either the PS model or the outcome model is
correctly specified, the bias of the estimation is negligible. In Table 2.1, when the
PS model is wrong (PS model 3), if we directly compare the two groups without co-
variate adjustment after matching (outcome models 2 and 3), the biases are large. In
contrast, if we perform outcome regression using patient-level covariates after match-
ing (outcome models 1, 4 and 5), the biases are greatly reduced. Although outcome
models 4 and 5 are not exactly correct (because they omit the hospital-level con-
founder and polynomial terms of the patient-level confounders), it still works well for
reducing bias. Similarly, when the outcome models are wrong (models 2 and 3), if
we use correct or almost correct PS models (models 1,4 and 5), the biases are greatly
reduced. Thus, the simulation results show that when either the PS or the outcome
model is almost correct, the biases of the proposed method are low.
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Second, the proposed method is more efficient than PS matching without subse-
quent outcome modeling. As we described in Section 2.2, the PS matching method
is equivalent to PS matching followed by outcome model 2 or 3. Table 2.1 shows
that the proposed methods using outcome model with covariate adjustment (out-
come models 1, 4 and 5) always have smaller variance compared to PS matching
without subsequent covariate adjustment (outcome model 2 and 3).
Third, we show that our method is more robust than outcome regression. The
biases for outcome regression are large when the outcome models are greatly misspec-
ified (model 2 and 3), and not negligible when outcome models are almost correct
(model 4 and 5). The proposed method combines outcome regression with PS match-
ing, and if the PS models are correct or almost correct (model 1, 4 and 5), the biases
are greatly reduced compared to outcome regression. Even when the PS models are
very wrong (model 3), the proposed method is still less biased than outcome regres-
sion.
Fourth, we show that the proposed method has comparable or better performance
than Li’s doubly robust IPW method in our simulation settings. Most of the biases
and variances for the proposed methods are smaller than those for Li’s method condi-
tional on same PS models and outcome models. Especially when either the PS model
or outcome model is very wrong, the biases from Li’s method are much larger than
the proposed method.
Fifth, in Scenario 1, the biases for matching within hospital are smaller compared
to across-hospital and modified across-hospital matchings. In particular, when either
the PS model or outcome are very wrong (PS model 3, outcome model 2 and 3),
the across-hospital and modified across-hospital matchings are much more biased
compared to within-hospital matching. One possible reason is that matching within
hospital achieves perfect balance on the hospital level, hence avoiding the potential
hospital-level confoundings. Its variances are slightly larger compared to matching
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across hospital and modified matching across hospital. A possible reason may be that
many patients cannot be successfully matched within the same hospital, so we lose a
large percentage of patients during matching. The low matching rate is a particular
common problem when hospital sizes are small. When the hospital size increases, the
variance of matching within hospital would be smaller (Scenario 2 and 3).
Sixth, the coverage probabilities for the proposed methods appear to be around
95% when using PS models 1,4 and 5 and outcome models 1,4 and 5.
Tables 2.3-2.6 show simulation results for Scenario 2 and 3 in which the hospital
sizes increase to 100 and random numbers between 30 and 170, respectively. As the
hospital sizes increase, the variances of the proposed methods are smaller than that in
Scenario 1, making the proposed methods much more efficient than Li’s method. Ad-
ditionally, the variances of within-hospital matching methods are still larger than but
closer to the modified across-hospital matching. The conclusion from the simulation
results for Scenario 2 and 3 are generally consistent with the above seven conclusions
for Scenario 1. It suggests that the proposed methods perform well in either small or
large hospital sizes.
Table A.1-A.12 show simulation results for matching with replacement and mod-
ified matching with replacement in three scenarios. The conclusions from Table A.1-
A.12 are generally consistent with matching without replacement. One remarkable
difference is that when the sample size is 30, matching with replacement and mod-
ified matching with replacement are more efficient than matching without replace-
ment. This makes sense because when the sample size is small, matching without
replacement greatly limits the number of matchings, but matching with replacement
greatly increases the chance of being matched. In contrast, when the sample size
increases to 100 or to a random number between 30 and 170, matching without re-
placement are more efficient than matching with replacement or modified matching
with replacement. This seems counter-intuitive, but actually the efficiency depends
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on the number of unique patients in matched data, instead of the total number of the
matched patients. In the medium or large hospitals, matching with replacement is
likely to create more matching pairs but the number of unique matched patients could
be smaller than matching without replacement because one patient can be matched
with multiple patients.
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Table 2.1: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use matching without replacement. The results are based on 1000 Monte Carlo data
sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
Bias MCSD Bias MCSD Bias MCSD Bias MCSD Bias MCSD
Outcome Regression
Only






PS Model 1 0.000 0.232 0.008 0.300 0.008 0.300 0.002 0.242 0.002 0.242
PS Model 2 0.000 0.245 0.006 0.289 0.006 0.289 0.003 0.257 0.003 0.257
PS Model 3 −0.004 0.206 1.189 0.261 1.189 0.261 0.002 0.237 −0.009 0.238
PS Model 4 0.000 0.234 0.008 0.275 0.008 0.275 0.003 0.244 0.003 0.244




PS Model 1 0.009 0.191 −0.142 0.279 −0.190 0.273 0.005 0.223 0.002 0.224
PS Model 2 0.003 0.186 0.414 0.343 0.179 0.232 0.052 0.201 0.000 0.204
PS Model 3 0.004 0.183 1.366 0.327 1.224 0.244 0.050 0.216 0.002 0.218
PS Model 4 0.005 0.196 −0.085 0.253 −0.190 0.240 0.009 0.224 0.015 0.226





PS Model 1 0.005 0.191 −0.118 0.269 −0.110 0.257 0.014 0.208 0.018 0.208
PS Model 2 0.002 0.181 0.346 0.307 0.250 0.221 0.045 0.195 0.004 0.198
PS Model 3 0.003 0.176 1.338 0.287 1.311 0.231 0.036 0.207 −0.002 0.209
PS Model 4 0.006 0.192 −0.078 0.235 −0.104 0.225 0.023 0.209 0.021 0.209
PS Model 5 0.006 0.195 −0.017 0.242 −0.056 0.228 0.010 0.214 0.013 0.213
Li et al method
PS Model 1 0.008 0.192 0.166 0.428 0.201 0.405 0.003 0.282 −0.003 0.282
PS Model 2 0.007 0.173 0.441 0.383 0.377 0.286 0.046 0.237 0.007 0.238
PS Model 3 0.004 0.168 1.361 0.308 1.283 0.219 −0.055 0.206 −0.094 0.207
PS Model 4 0.008 0.191 0.235 0.401 0.215 0.380 0.007 0.280 −0.003 0.280
PS Model 5 0.007 0.222 0.006 0.530 0.008 0.494 0.004 0.334 0.004 0.333
19
Table 2.2: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for outcome regression method)
and 5 outcome models described in Section 2.3. We use matching without replacement. The results are based on
1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
ASE CP ASE CP ASE CP ASE CP ASE CP
Outcome Regression
Only






PS Model 1 0.241 0.962 0.406 0.994 0.362 0.987 0.264 0.968 0.265 0.968
PS Model 2 0.251 0.960 0.422 0.993 0.375 0.989 0.274 0.968 0.276 0.970
PS Model 3 0.211 0.957 0.343 0.029 0.311 0.018 0.261 0.973 0.262 0.973
PS Model 4 0.241 0.960 0.406 0.998 0.362 0.992 0.264 0.961 0.265 0.963




PS Model 1 0.202 0.957 0.330 0.965 0.305 0.930 0.228 0.951 0.230 0.955
PS Model 2 0.193 0.954 0.286 0.657 0.291 0.955 0.217 0.956 0.221 0.961
PS Model 3 0.182 0.953 0.274 0.005 0.277 0.005 0.223 0.955 0.227 0.961
PS Model 4 0.202 0.957 0.331 0.986 0.305 0.959 0.229 0.949 0.230 0.949





PS Model 1 0.197 0.951 0.329 0.976 0.298 0.966 0.221 0.957 0.221 0.960
PS Model 2 0.184 0.950 0.284 0.745 0.277 0.901 0.206 0.952 0.209 0.961
PS Model 3 0.175 0.954 0.274 0.002 0.265 0.000 0.215 0.950 0.217 0.958
PS Model 4 0.197 0.957 0.330 0.989 0.298 0.982 0.221 0.957 0.221 0.956
PS Model 5 0.197 0.945 0.331 0.991 0.299 0.985 0.221 0.956 0.222 0.960
Li et al method
PS Model 1 0.172 0.918 0.429 0.888 0.392 0.864 0.235 0.923 0.235 0.919
PS Model 2 0.151 0.912 0.340 0.674 0.315 0.726 0.204 0.911 0.204 0.916
PS Model 3 0.136 0.886 0.251 0.002 0.227 0.000 0.168 0.882 0.167 0.853
PS Model 4 0.171 0.917 0.421 0.861 0.389 0.864 0.233 0.926 0.233 0.926
PS Model 5 0.207 0.935 0.521 0.954 0.479 0.952 0.281 0.939 0.280 0.936
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Table 2.3: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use matching without replacement. The results are based on 1000 Monte Carlo data
sets with number of hospitals equals to 30 and hospital size equals to 100.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
Bias MCSD Bias MCSD Bias MCSD Bias MCSD Bias MCSD
Outcome Regression
Only






PS Model 1 0.001 0.104 0.016 0.134 0.016 0.134 0.004 0.108 0.004 0.108
PS Model 2 −0.004 0.106 0.005 0.126 0.005 0.126 −0.001 0.110 −0.001 0.110
PS Model 3 0.000 0.099 1.190 0.134 1.190 0.134 0.001 0.113 −0.002 0.112
PS Model 4 −0.003 0.103 0.008 0.117 0.008 0.117 −0.001 0.108 −0.001 0.108




PS Model 1 0.001 0.098 −0.034 0.173 −0.143 0.151 0.010 0.120 0.015 0.121
PS Model 2 0.000 0.097 0.409 0.288 0.124 0.130 0.010 0.104 −0.006 0.104
PS Model 3 0.000 0.093 1.366 0.261 1.192 0.139 0.010 0.108 −0.005 0.108
PS Model 4 −0.001 0.100 −0.012 0.162 −0.142 0.134 0.010 0.121 0.014 0.121





PS Model 1 0.001 0.098 −0.022 0.133 −0.015 0.129 0.017 0.106 0.017 0.106
PS Model 2 0.000 0.094 0.292 0.218 0.266 0.121 0.014 0.100 0.003 0.100
PS Model 3 0.000 0.092 1.318 0.206 1.311 0.132 0.000 0.105 −0.012 0.105
PS Model 4 −0.001 0.099 −0.018 0.117 −0.019 0.111 0.014 0.106 0.014 0.106
PS Model 5 −0.002 0.098 −0.005 0.116 −0.009 0.111 0.010 0.105 0.010 0.105
Li et al method
PS Model 1 0.001 0.114 0.043 0.406 0.055 0.377 −0.006 0.224 −0.007 0.223
PS Model 2 0.002 0.090 0.424 0.298 0.325 0.165 0.011 0.123 −0.002 0.123
PS Model 3 0.000 0.088 1.351 0.247 1.257 0.125 −0.088 0.110 −0.100 0.109
PS Model 4 0.001 0.113 0.069 0.392 0.058 0.366 −0.005 0.219 −0.007 0.218
PS Model 5 0.000 0.129 −0.025 0.528 −0.023 0.487 −0.006 0.279 −0.006 0.277
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Table 2.4: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use matching without replacement. The results are
based on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size equals to 100.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
ASE CP ASE CP ASE CP ASE CP ASE CP
Outcome Regression
Only






PS Model 1 0.111 0.972 0.189 0.992 0.170 0.988 0.124 0.977 0.124 0.977
PS Model 2 0.112 0.966 0.191 0.996 0.172 0.992 0.125 0.977 0.125 0.977
PS Model 3 0.105 0.963 0.173 0.000 0.158 0.000 0.130 0.973 0.130 0.973
PS Model 4 0.111 0.971 0.189 0.998 0.171 0.996 0.124 0.978 0.124 0.978




PS Model 1 0.108 0.965 0.178 0.959 0.165 0.880 0.122 0.952 0.123 0.950
PS Model 2 0.104 0.959 0.155 0.371 0.159 0.920 0.117 0.962 0.118 0.967
PS Model 3 0.099 0.959 0.150 0.000 0.152 0.000 0.121 0.974 0.122 0.971
PS Model 4 0.108 0.965 0.178 0.970 0.165 0.912 0.122 0.951 0.123 0.950





PS Model 1 0.104 0.970 0.177 0.993 0.160 0.987 0.118 0.972 0.118 0.972
PS Model 2 0.097 0.960 0.154 0.529 0.147 0.579 0.109 0.971 0.109 0.970
PS Model 3 0.094 0.957 0.150 0.000 0.144 0.000 0.115 0.966 0.116 0.967
PS Model 4 0.104 0.964 0.177 0.996 0.160 0.998 0.118 0.973 0.118 0.972
PS Model 5 0.104 0.960 0.177 0.996 0.160 0.997 0.118 0.972 0.118 0.971
Li et al method
PS Model 1 0.106 0.935 0.284 0.950 0.264 0.932 0.155 0.940 0.155 0.940
PS Model 2 0.084 0.925 0.188 0.422 0.176 0.517 0.114 0.928 0.114 0.926
PS Model 3 0.075 0.899 0.137 0.000 0.125 0.000 0.093 0.807 0.093 0.774
PS Model 4 0.106 0.935 0.282 0.937 0.263 0.932 0.155 0.938 0.155 0.938
PS Model 5 0.116 0.942 0.315 0.978 0.293 0.966 0.171 0.943 0.171 0.943
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Table 2.5: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use matching without replacement. The results are based on 1000 Monte Carlo data
sets with number of hospitals equals to 30 and hospital size follows uniform distribution U(30,170).
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
bias MCSD bias MCSD bias MCSD bias MCSD bias MCSD
Outcome Regression
Only






PS Model 1 −0.001 0.107 0.011 0.140 0.011 0.140 0.002 0.113 0.002 0.113
PS Model 2 −0.001 0.107 0.007 0.128 0.007 0.128 0.000 0.113 0.000 0.113
PS Model 3 −0.001 0.100 1.188 0.131 1.188 0.131 −0.001 0.113 −0.004 0.113
PS Model 4 −0.001 0.104 0.012 0.120 0.012 0.120 0.002 0.111 0.002 0.111




PS Model 1 0.002 0.102 −0.032 0.184 −0.142 0.160 0.010 0.124 0.015 0.125
PS Model 2 0.002 0.099 0.374 0.309 0.118 0.136 0.011 0.105 −0.003 0.105
PS Model 3 0.001 0.097 1.344 0.279 1.194 0.135 0.012 0.113 −0.001 0.114
PS Model 4 0.001 0.103 −0.008 0.170 −0.139 0.141 0.012 0.124 0.015 0.125





PS Model 1 −0.001 0.101 −0.026 0.143 −0.020 0.137 0.012 0.109 0.012 0.108
PS Model 2 0.000 0.095 0.265 0.232 0.256 0.129 0.012 0.102 0.002 0.102
PS Model 3 −0.001 0.094 1.299 0.214 1.306 0.132 −0.002 0.109 −0.012 0.109
PS Model 4 −0.001 0.098 −0.017 0.119 −0.019 0.114 0.012 0.107 0.012 0.106
PS Model 5 −0.001 0.099 −0.003 0.120 −0.008 0.115 0.009 0.107 0.009 0.107
Li et al method
PS Model 1 0.001 0.109 0.060 0.247 0.075 0.235 0.000 0.162 −0.001 0.161
PS Model 2 −0.002 0.094 0.391 0.327 0.314 0.167 0.005 0.130 −0.006 0.130
PS Model 3 0.000 0.090 1.326 0.263 1.251 0.124 −0.093 0.113 −0.104 0.113
PS Model 4 0.001 0.109 0.085 0.239 0.078 0.226 0.000 0.161 −0.001 0.161
PS Model 5 0.001 0.116 0.005 0.265 0.008 0.250 0.003 0.173 0.003 0.172
23
Table 2.6: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression method)
and 5 outcome models described in Section 2.3. We use matching without replacement. The results are based on
1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size follows uniform distribution
U(30,170).
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
ASE CP ASE CP ASE CP ASE CP ASE CP
Outcome Regression
Only






PS Model 1 0.111 0.955 0.189 0.993 0.170 0.987 0.124 0.964 0.124 0.964
PS Model 2 0.112 0.959 0.190 0.998 0.171 0.996 0.125 0.965 0.125 0.965
PS Model 3 0.104 0.958 0.173 0.000 0.158 0.000 0.129 0.976 0.129 0.973
PS Model 4 0.111 0.968 0.189 1.000 0.170 0.997 0.124 0.970 0.124 0.971




PS Model 1 0.108 0.963 0.178 0.939 0.165 0.870 0.122 0.944 0.123 0.942
PS Model 2 0.104 0.962 0.155 0.422 0.158 0.932 0.117 0.963 0.117 0.964
PS Model 3 0.099 0.951 0.150 0.000 0.152 0.000 0.121 0.957 0.122 0.962
PS Model 4 0.108 0.959 0.178 0.961 0.165 0.889 0.122 0.942 0.123 0.942





PS Model 1 0.104 0.955 0.177 0.984 0.160 0.977 0.118 0.960 0.118 0.960
PS Model 2 0.097 0.955 0.154 0.575 0.147 0.602 0.109 0.966 0.109 0.966
PS Model 3 0.094 0.951 0.150 0.000 0.144 0.000 0.115 0.958 0.116 0.956
PS Model 4 0.104 0.968 0.177 0.997 0.160 0.993 0.118 0.969 0.118 0.970
PS Model 5 0.104 0.961 0.177 0.996 0.160 0.994 0.118 0.968 0.118 0.968
Li et al method
PS Model 1 0.104 0.936 0.264 0.930 0.246 0.904 0.146 0.933 0.145 0.932
PS Model 2 0.084 0.928 0.189 0.465 0.178 0.548 0.115 0.915 0.115 0.920
PS Model 3 0.075 0.909 0.137 0.000 0.125 0.000 0.093 0.782 0.093 0.756
PS Model 4 0.104 0.934 0.263 0.931 0.246 0.925 0.145 0.932 0.145 0.931
PS Model 5 0.112 0.935 0.286 0.954 0.266 0.949 0.156 0.940 0.156 0.940
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2.4 Application
Cardioplegia is a blood or crystalloid based solution that induces myocardial elec-
trical silence and provides buffers and basic cellular nutrients to myocardium during
cardiac surgery. Del Nido cardioplegia (DC) and blood-based cardioplegia (BC) are
two types of cardioplegia used in cardiac surgery. We apply our methods to compare
the post-operative length of stay (LOS) (days) between DC and BC using multi-
center clinical data. The data contain 11 hospitals and 14,339 patients in total. The
hospital sizes vary between 40 and 4,211 and median hospital size is 1,077. The
patients received either DC (n = 5, 005) or BC (n = 9, 394). The possible patient
characteristics associated with the post-operative LOS and treatment assignment are
age, gender, hypertension, diabetes, previous cardiovascular disease and etc. Imbal-
ances of the patient characteristics and post-operative LOS were observed between
hospitals (Table 2.7).
Table 2.7: Distribution of post-operative length of stay (days), age, gender, hyper-
tension, diabetes and previous cardiovascular disease by hospital.
Hospital Post-operative LOS (mean) Age (mean) Female (%) Hypertension (%) Diabetes (%) Previous cardiovascular disease (%)
1 7.4 62.6 34.4 71.9 27.0 14.0
2 6.3 65.2 30.0 90.0 40.0 7.5
3 10.7 63.0 31.1 84.9 42.5 5.3
4 7.6 65.6 28.9 85.2 35.9 5.9
5 7.5 69.1 31.2 85.1 41.6 3.5
6 7.3 66.7 32.1 92.1 43.3 5.8
7 7.6 66.7 30.8 87.4 42.9 3.6
8 7.2 67.5 31.2 81.9 38.4 6.0
9 8.3 64.7 33.4 85.6 40.9 4.4
10 12.2 67.3 30.3 89.4 39.4 7.6
11 8.2 63.1 37.1 85.4 46.7 7.3
We perform the data analysis using the proposed method. According to the
simulation results, we choose matching within hospitals without replacement as it
generally has the best performance when hospital sizes are larger than 30. We use
the fixed-effect PS model and outcome models because we assume there were un-
measured hospital-level confounders. We include the linear forms of all the possible
confounders mentioned above in both the PS and outcome models. Table 2.8 shows
the results of the analyses. The proposed method shows that the post-operative LOS
for DC is slightly longer than that for BC although the difference is not significant.
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The standard error of the proposed method is smaller compared to other methods.
δ: difference in the post-operative LOS (DC minus BC). SE: standard error.
Table 2.8: Estimation of the difference in the post-operative LOS (days) between DC
and BC.
Method δ̂ ŜE(δ̂) P-value
Outcome regression 0.001 0.117 0.503
PS matching −0.058 0.118 0.311
Li et al method 0.110 0.127 0.193
Proposed method 0.068 0.114 0.275
2.5 Discussion
In this chapter, we propose doubly robust PS matching methods for estimating the
ATE in clustered observational data. The proposed methods combine PS matching
and outcome regression while accounting for the hierarchical nature of the data. We
further study and compare various matching methods for clustered data, including
matching within hospital, across hospital and modified across hospital. The simula-
tion results show that the proposed methods perform well for either small or large
cluster sizes.
We show that as long as we fit either PS model or outcome model correct or
relatively correct, the bias of proposed method is negligible. We recommend to use
hierarchical models instead of single-level models for causal inference in clustered data.
It is important to include as many important covariates as possible when fitting PS
or outcome model. Regarding the matching approaches, matching within hospital
has best performance on reducing bias. Also if people suspect there are important
hospital-level confounders unobserved which likely happen in reality, we recommend
matching within hospital. As we stated in Section 2.4, matching with replacement is
less efficient when hospital sizes are medium or large. Our results are consistent with
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the previous research by Austin (2014) which claimed that matching with replacement
does not reduce or even have larger standard errors of the ATE estimates compared
to matching without replacement. Yet when hospital sizes are very small, matching
with replacement should be a better choice for reducing variance. In this chapter,
we did not study how to decide the caliper to achieve best baseline balance between
groups in this chapter.
We use bootstrap approach to calculate standard errors. Abadie and Imbens
(2008) claimed that bootstrap standard errors for matching estimator are not valid
and proposed an alternative way for standard error for nearest neighbor matching es-
timator. However, we use caliper matching and consider matching in clustered data,
which make the estimation of standard error much more challenging. When we use
matching with replacement, the coverage probabilities seem not close to the nominal
level, which suggests that the bootstrap standard errors are more problematic when
patients have different weights in the matched data. Although we did not propose a
method to solve this in this chapter, it may be an interesting research topic in future.
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CHAPTER III
Augmented Double Inverse-Weighted Method for
Causal Inference Based on Restricted Mean
Lifetime
3.1 Introduction
In medical studies, it is often of interest to compare the survival outcomes between
treatment groups using observational data. In observational studies, the distributions
of patient baseline covariates are often different between treatment groups. To esti-
mate the treatment effect, it is therefore necessary to adjust for covariate imbalances.
Since being proposed in 1972 (Cox , 1992), the Cox model has been a dominant
method of covariate adjustment in survival analysis and is often used to compare
hazards between groups. However, if the proportional hazard assumption is violated,
the hazard ratio estimated from the Cox model is difficult to interpret. In such cases,
it is more reasonable to compare survival times instead of hazards between groups.
As the durations of medical studies are often finite, the time to the event of interest
may be administratively censored. Therefore, the restricted mean lifetime instead of
mean lifetime has been widely used in medical research.
This Chapter is motivated by a study of cardiac surgery, in which we were interest-
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ed in comparing the restricted mean lifetime between two types of cardiac surgeries
for patients with advanced heart failure (AHF). Heart transplants used to be the
dominant treatment for AHF. However, during the last decade, the implantation of
ventricular assist devices (VAD) has grown dramatically and become the most popu-
lar treatment. Depending on patients’ clinical conditions, VAD implantations can be
performed on either the left side only (LVAD) or both sides (BiVAD) of the heart.
The cardiac surgeons were interested in comparing the LVAD and BiVAD in terms of
restricted mean lifetime. However, the comparison was challenging due to two rea-
sons. The first one was that two types of VAD implantations were not randomized,
which meant that the baseline patient covariates were not balanced between groups;
patients receiving BiVAD had more severe conditions than those receiving LVAD. For
example, patients were more likely to receive BiVAD implantation if s/he was expe-
riencing the critical cardiogenic shock or her/his central venous pressure was greater
than 15 mmHg before the surgery. The second reason was that it is not uncom-
mon that patients receive heart transplants after the VAD implantations, which may
not be balanced between the two groups. We knew that the patients with a worse
post-implant situation were more likely to receive heart transplants. For example, it
has been shown that the patients with high post-operative creatinine and albumin
were more likely to need a subsequent heart transplant compared to other patients.
Hence, the time of receiving heart transplant was not independent of survival time
given treatment assignment and patient baseline covariates. Various approaches have
been proposed to handle the events like transplant (Zhang and Wang , 2012, 2013). In
this chapter, we treat the heart transplant as dependent censoring and then estimate
the treatment-specific difference in restricted mean lifetimes, had no patients received
heart transplants. To reach this goal, we need to handle both group-level baseline
imbalance and dependent censoring.
Generally, two strategies can be used to overcome these two challenges. The first
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strategy is directly modeling the relationship between survival time and covariates
using group-specific models, then average the fitted mean lifetimes over the entire
sample (Chen and Tsiatis , 2001; Zhang and Schaubel , 2011). Zhang and Schaubel
(2011) further improved this strategy by incorporating weighting methods to accom-
modate the dependent censoring. The second strategy is using inverse probability
weighting to equalize group-specific covariate distributions and handle dependent
censoring. Instead of modeling survival outcome, this strategy only requires model-
ing treatment assignment and censoring. In our motivating study, the relationship
between survival time and covariates was complicated and hence difficult to model.
However, the treatment assignment and transplant decision were much better under-
stood. The surgeons typically have standard protocols to decide which treatment to
use according to the patient’s conditions. Therefore, we prefer the second strategy.
Inverse probability of treatment weighting (IPTW) was proposed by Robins et al.
(1994) to adjust baseline covariate imbalances between treatment groups. To solve
the dependent censoring problem, inverse probability of censoring weighting (IPCW)
was proposed by Robins and Rotnitzky (1992). To addressing both baseline imbal-
ances and dependent censoring, several researchers have proposed combining IPTW
and IPCW. Anstrom and Tsiatis (2001) proposed a double weighted method for
time-lagged data. Schaubel and Wei (2011) proposed a double weighted estimator
to estimate the cumulative hazard and restricted mean lifetime. Zhang and Schaubel
(2012b) developed a double robust estimator using both IPTW and IPCW to esti-
mate the restricted mean lifetime. However, one disadvantage of inverse probability
weighting (IPW) methods is inefficiency, for which various strategies have been pro-
posed. For example, Zhang et al. (2008) proposed a broadly applicable augmentation
approach to improve efficiency using baseline auxiliary covariates. More recently,
Zhang (2015) developed a robust method to use patient covariates to improve effi-
ciency in randomized clinical trials which made no assumptions of the relationship
30
between survival outcome and covariates.
In this chapter, we propose a method to estimate the treatment-specific differ-
ence in potential restricted mean lifetimes, had no patients received heart transplant,
where the heart transplant is treated as dependent censoring for the potential life-
time. Specifically, we first derive an estimator that combines IPTW and IPCW to
account for the imbalance in baseline characteristics and receipt of heart transplant,
respectively. Then we propose augmentation method to improve the efficiency of the
estimation.
The remainder of this chapter is organized as follows. In Section 3.2, we describe
the notation and data structure. In Section 3.3, we propose our method and state its
connection to existing methods. We evaluate the performance of our method using
a simulation study in Section 3.4. In Section 3.5, we apply the method to cardiac
surgery data obtained from the Interagency Registry for Mechanically Assisted Cir-
culatory Support (INTERMACS). Finally, we conclude and discuss in Section 3.6.
3.2 Notation and Data Structure
Let A indicate two non-randomized treatment groups (A = 1 means treatment,
A = 0 means control). We denote the survival time without heart transplant by T .
Let C denote dependent censoring (heart transplant). In practice, one observes the
minimum of the survival time and time to censoring. We let U = T ∧ C denote the
observation time and ∆ = I(T ≤ C) denote the indicator for observing the death time.
We let Z be the baseline covariate vector, and Z(t) be the time-dependent covariate at
time t. Note that Z(0) would be the elements of Z. We let Z̃(t) = {Z(u);u ∈ [0, t)} be
the history of the baseline and time-dependent covariates up to time t. The observed
data can be summarized as Oi = {Ai, Ui,∆i, Zi, Z̃i(ui)}, where the Oi is assumed
to be identically and independent distributed (i.i.d.) across i = 1, ..., n. Note that
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the Oi is redundant because Z̃(t) includes all the baseline covariate Zi, but it is more
convenient for presentation. We denote the observed event process and at-risk process
by Ni(t) = I(Ui ≤ t,∆ = 1) and Yi(t) = I(Ui ≥ t), respectively.
We define the parameter of interest using the potential outcome framework pro-
posed by Rubin (1974, 1978). Let T k (k = 0,1) denote the potential lifetime for a
randomly selected patient from the population if, possibly contrary to fact, s/he were
assigned to group k, and not censored by a heart transplant. We make the assump-
tion that there are no unmeasured baseline confounders. We also assume that Ci is
conditionally independent of Ti given {Ai, Zi, Z̃i(t)}, formally expressed as
lim
ξ→0
ξ−1P{t ≤ Ui < t+ ξ,∆i = 0|Ui ≥ t, Ai, Z̃i(t), Ti}
= lim
ξ→0
ξ−1P{t ≤ Ui < t+ ξ,∆i = 0|Ui ≥ t, Ai, Z̃i(t)}.
Our estimand δ is the difference in restricted mean lifetime up to time L between
two treatment groups, had no patients received heart transplants. Let µk denote the
restricted mean lifetime for group k and Sk(t) = P (T
k > t), then
δ = µ1 − µ0













We first introduce existing methods and their connections with the proposed method.
Let Λk(t) denote the marginal cumulative hazard function of T
k. We estimate the
group-specific restricted mean lifetime µk by
∫ t
0
exp{−Λ̂k(u)}du. If we assume that,
possibly contrary to fact, all patients were assigned to group k, and survival time
is independent of censoring given their treatment assignment, i.e. T |= C|A. Based
on these assumptions, we can use the Nelson-Aalen estimator to estimate for the












{dNik(t)− Yik(t)dΛk(t)} = 0.
In observational studies, not everyone is assigned to group k and there are baseline
imbalances between groups. If we assume C is independent of T given A and there
are no unmeasured baseline confounder, the unbiased IPTW estimating equation for







where Aik = I(Ai = k) and pik(θ̂) estimates Pr(Aik = 1|Zi) through a model with








where wik(θ̂) = I(Aik = 1)/pik(θ̂).
In observational studies, the assumption that C is independent of T given A is too
restrictive. A more realistic assumption would be that C is independent of T given
{A,Z, Z̃(t)} as assumed in this chapter. Under this assumption, the IPTW estimator
is biased as it does not account for the dependent censoring. As IPCW can be used
to handle dependent censoring, if we can incorporate IPTW and IPCW in a proper
way, we can obtain an unbiased estimator.
Before explaining the proposed method, we will first introduce the coarsening
concept first. We say that the full data one would like to observe are coarsened because
of treatment assignment and censoring (Tsiatis , 2007). For example, if Aik = 0, T
k
i





partially observed, we say it is less coarsened; if Aik = 1, Ci ≥ T ki , T ki is completely
observed, it is not coarsened. By Tsiatis (2007), one can inverse weight an unbiased
estimating function based on full data by the probability of observing the complete
case (not being coarsened), i.e. the probability of being assigned to treatment k
and not being censored. Based on this principle, we can combine IPTW and IPCW
into a single inverse probability weighting framework and derive the unbiased double






where pci(γ̂, t) estimates Pr{Ci ≥ t|Ai, Zi, Z̃i(t)} through a model like the Cox model
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with parameter γ. By solving the estimating equation, the double inverse probability












Here wci (γ̂, t) = I(Ci ≥ t)/pci(γ̂, t). Please note that, Λ̂DIPWk (t) are consistent only
if the models for P (Aik = 1|Zi) and P{Ci ≥ t|Ai, Zi, Z̃i(t)} are correctly specified.
As stated in Section 3.1, we assume that we are able to correctly specify both mod-
els in our motivating study, and therefore we can consistently estimate Λk(t) using
Λ̂DIPWk (t).
3.3.2 Proposed Augmentation Method
So far we have introduced IPW approaches that use baseline and time-varying co-
variates to reweight patients in order to equalize the covariate distributions between
groups. As we stated in Section 3.1, one drawback of the simple inverse probability
weighting method is inefficiency. In order to improve the efficiency of the DIPW
estimator, we propose an augmentation method. Motivated by Tsiatis (2007) and
Zhang et al. (2008), we construct unbiased augmented double weighted estimating e-












In this equation, hk(t, Zi) is an arbitrary function of baseline covariate Zi at time t.












∣∣Zi}] = E[hk(t, Zi)dtE{Aik−pik(θ̂)pik(θ̂) ∣∣Zi}] = 0. Therefore E-
quation (3.2) is still an unbiased estimating equation. The rationale for adding the sec-
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ond part of the left part of Equation (3.2), is that if we can find an ‘optimal’ hk(t, Zi),
we may reduce the standard deviation of the resulting estimator. It is straightfor-










0. Hence the estimators derived from Equation (3.2) are M-estimators. According to
the theory of M-estimators, we show that the asymptotic variance of the estimator



























, which is the variance of the left part of Equation (3.2).
By straightforward algebra, we can show that hk(t, Zi) that minimizes the above
asymptotic variance is E(dMik|Zi, Aik = 1). This solution involves a conditional ex-
pectation, which needs to be estimated from a model that we inevitably misspecify in
reality. If we misspecify the model, the efficiency is not guaranteed to be improved,
and may be even worsen. Thus, this may not be a good strategy for improving the
efficiency. Instead, we apply the augmentation strategy proposed by Zhang (2015).
Specifically, we consider a subclass where hk(t, Zi) is of the form β
T
k (t)gk(Zi), and
where gk(Zi) are basis functions in Zi, including intercept, linear term, possibly poly-
nomial terms and interaction terms in Zi. Then we derive the optimal hk(t, Zi) in
this subclass, which is equivalent to finding the optimal βk(t). Therefore we only
need to identify βk(t) to minimize the variance of the estimating equation. We show
that the optimal βk(t) that minimizes the variance of the estimating equation can be



















































if we correctly model treatment assignment and dependent censoring. Note that since
we do not know dΛk(t), we substitute it by its unbiased estimator dΛ̂
DIPW
k (t). The
estimator developed using this strategy is guaranteed to improve efficiency compared
to the double inverse weighted estimator. The reason is that when βk(t) = 0, the
estimating equation reduces to the DIPW estimating equation. In other words, this
subclass includes the DIPW estimator as a special case. Since we minimize variance
within this subclass, the optimal estimator must be equivalent to or better than the
DIPW estimator, in terms of efficiency.
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3.3.3 Proposed Augmented Double Inverse Weighted Estimators
We fit models for treatment assignment and censoring conditional on Ai and Zi. First,
we model treatment assignment by logistic regression:
logit{P (Aik = 1|Zi)} = θTXi,
where Xi = (1, Zi). We assume that we correctly model the treatment assignment,
thus the maximum likelihood estimator for θ, θ̂ consistently estimate θ. Secondly, we
assume the hazard model of censoring is a Cox model:
λ(t|Vi) = λ0(t)exp(γTVi),
where Vi = {Ai, Zi, Zi(t)}. We assume it is correctly specified, thus Λ0(t) and γ
can be consistently estimated by the Breslow estimator and the maximum partial
likelihood estimator, respectively. Therefore, the proposed augmented double inverse













Sk(t) can be estimated by Ŝk(t) = e




and hence δ̂ = µ̂1 − µ̂0. The asymptotic properties of the proposed estimator are de-
rived in Appendix B.1.
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3.4 Simulation Study
We perform a simulation study to evaluate the performance of our proposed meth-
ods. The reported results are based on 1000 Monte Carlo data sets. The sample size
n is 500 for each data set.
Each Monte Carlo data set is generated as follows: baseline covariate vector Z
= (Z1, Z2, Z3)
T , with Z1, Z2 and Z3 generated from multivariate normal distribution
with mean 0, unit variance and all pairwise correlations 0. All the normal covariates
are truncated at ±3 to satisfy the regularity conditions. The treatment indicator
A is generated from the Bernoulli distribution with parameter expit(1.5Z1 − Z2).
The censoring time C is generated from the exponential distribution with parameter
0.15exp(1.5Z3 + 0.3Z(t)). To generate the time-varying covariate Z(t), we first gen-
erate a latent variable V from the standard normal distribution, then generate Z(t)
as a binary variable depending on V and A, Z(t) = I(0.5 + (5 + V − A)t ≥ 5). t∗
= 4.5/(t + V − A) is the time that Z(t) jumps from 0 to 1. The survival time T is
generated from the three scenarios below.
The details of generating survival time T are in Appendix B.2. Briefly, in the
first scenario, the survival time T is generated from a Cox model with an exponential
baseline survival time distribution. In the second scenario, T is generated from an
accelerated failure time (AFT) model with lognormal baseline survival time distribu-
tion. In the third scenario, T is generated from a Cox model with lognormal baseline
survival time distribution.
In our simulation, we use the correct treatment assignment model and censoring
model for the estimation of the restricted mean lifetime. Specifically, we use the
treatment assignment model
logit{P (Ai = 1|Zi)} = β1Z1 + β2Z2,
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and the Cox model for censoring
λc(t|Zi, Zi(t), Ai) = λc0(t)exp{γ1Z3,i + γ2Zi(t)},
where λc(t|Zi, Zi(t), Ai) is the conditional hazard for censoring. For the proposed
method, when we do augmentation, we let gk(Z, u) be a basis function including
intercept and linear forms of all baseline covariates, i.e. gk(Z, u) = (1, Z1, Z2, Z3)
T .
We estimate the standard error via bootstrap approach. In our simulation study, we
are interested in the restricted mean lifetime up to L = 1.5. We include a detailed
practical implementation procedure in Appendix B.3.
Table 3.1: Estimation of the difference in restricted mean lifetimes between treatment
and control. The results are based on 1000 Monte Carlo datasets. Sample
size n = 500.
δ̂ µ̂1 µ̂0
Method Bias ESD ASE CP RE Bias ESD ASE CP Bias ESD ASE CP
Scenario 1
N-A −0.457 0.053 0.053 0.00 −0.175 0.038 0.038 0.00 0.282 0.038 0.036 0.00
IPTW −0.056 0.074 0.084 0.90 0.016 0.046 0.049 0.96 0.072 0.069 0.067 0.75
DIPW −0.026 0.084 0.090 0.94 1 0.000 0.050 0.052 0.96 0.027 0.077 0.073 0.91
Proposed 0.008 0.077 0.083 0.96 1.29 0.015 0.048 0.055 0.95 0.007 0.070 0.066 0.92
Scenario 2
N-A −0.319 0.047 0.046 0.00 −0.115 0.035 0.034 0.07 0.204 0.031 0.032 0.00
IPTW −0.050 0.077 0.072 0.85 0.016 0.043 0.040 0.93 0.065 0.070 0.059 0.70
DIPW −0.024 0.095 0.086 0.91 1 −0.001 0.047 0.043 0.94 0.023 0.087 0.070 0.87
Proposed 0.001 0.090 0.087 0.93 1.19 0.010 0.044 0.046 0.95 0.009 0.082 0.075 0.92
Scenario 3
N-A −0.430 0.048 0.047 0.00 −0.157 0.034 0.033 0.00 0.273 0.034 0.034 0.00
IPTW −0.066 0.070 0.075 0.85 0.021 0.047 0.047 0.95 0.086 0.061 0.058 0.62
DIPW −0.025 0.090 0.086 0.93 1 −0.002 0.050 0.050 0.95 0.022 0.078 0.069 0.90
Proposed −0.009 0.084 0.084 0.96 1.22 0.014 0.047 0.055 0.96 0.005 0.073 0.066 0.93
Bias:Monte Carlo bias. ESD: Monte Carlo standard deviation. ASE: Monte Carlo
average of estimated standard errors. CP: coverage probability of nominal 95% Wald
confidence intervals. RE: Monte Carlo mean squared error for the DIPW estimator
divided by that for the indicated estimator
We use the proposed method to estimate the restricted mean lifetime and compare
its performance with Nelson-Aalen, IPTW and DIPW methods in three scenarios.
Under all scenarios, the Nelson-Aalen estimator greatly underestimates the difference
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of restricted mean lifetime between groups, which leads to large bias, as it does
not account for both baseline imbalances and dependent censoring. The bias of the
IPTW method is much smaller compared to the Nelson-Aalen method because it
accounts for the baseline imbalances between groups. However, there are still some
bias as the IPTW method does not account for the dependent censoring. Both DIPW
and the proposed method are approximately unbiased and the coverage probabilities
approximately achieve the nominal levels.
We compare the efficiency of the unbiased estimators which are DIPW and the
proposed estimators. Compared to the DIPW estimator, the variances of the pro-
posed estimators are smaller under all scenarios. We use relative efficiency to quantify
the difference in efficiency between DIPW and the proposed method. The relative
efficiency is defined as the ratio of the mean squared errors of DIPW and the proposed
estimators. Under the three scenarios, the relative efficiencies are between 1.19 and
1.29 for δ̂, which suggests that the proposed method improves efficiency in different
situations of survival outcome distributions and generating models.
3.5 Application
We apply the proposed method to a cardiac surgical data set obtained from IN-
TERMACS. It contains 5,856 AHF patients who received VAD implantations from
2008 to 2014. Among these patients, 5,672 (96.9%) received LVAD and the other 184
(3.1%) received BiVAD. We are interested in comparing the restricted mean lifetime
between LVAD and BiVAD up to 365 days. Approximately 58.4% of the survival
time was administratively censored, and 1.4% received heart transplants after VAD
implantations. As stated in previous sections, we treat the heart transplant as de-
pendent censoring. The data contains a rich set of covariates that are expected to be
related to survival outcome, and decisions regarding treatment and transplant. Based
41
on cardiac surgeons’ recommendation, we identified variables for the estimation of the
restricted mean lifetime by the proposed method. Specifically, 7 variables were relat-
ed to treatment assignment, including 5 variables measured within 48 hours before
the implantation surgery–extracorporeal membrane oxygenation (ECMO), mechani-
cal ventilation, intra-aortic balloon pump, dialysis or ultrafiltration and feeding tube,
and also whether central venous pressure was larger than 15 mmHg and INTERMA-
CS profile. Eight variables were related to the transplant decision, including age,
gender, race, creatinine, albumin, number of infections, device strategy, and INTER-
MACS profile, where the number of infections is a time-varying covariate. Up to 13
variables were thought to be related to survival outcome, including age, gender, race,
the Elixhauser comorbidity index, hemoglobin and diastolic blood pressure.
Preliminary analyses (Table 3.2) showed, as expected, that there were imbalances
in baseline covariates between BiVAD and LVAD. Generally, the patients in BiVAD
group needed more clinical interventions prior to surgery, which implied that they were
more ill compared to the patients in LVAD. In particular, there were large imbalances
in the interventions within 48 hours before surgery, including ECMO, ventilation,
IABP, dialysis and feeding tube. The percentage of central venous pressure higher
than 15 mmHg is larger for BiVAD patients.
We fit a logistic model for treatment assignment and a Cox model for the time
to receive heart transplants after VAD implantations. Then we applied the proposed
method to estimate the difference of the restricted mean lifetime up to 365 days.
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Table 3.3 shows the estimates of the restricted mean lifetime for the two treat-
Table 3.2: Characteristics of the study cohort stratified by treatment group
Patient Characteristic Category Overall LVAD BiVAD P-value
Age (mean± sd) 62.3± 11.2 62.4± 11.2 59.8± 12.4 0.002
Female (n, %) 1152, 19.7 1115, 19.7 37, 20.1 0.954
Race (n, %) White 4182, 71.4 4059, 71.6 123, 66.8 0.106
Black 1260, 21.5 1219, 21.5 41, 22.3
Other 414, 7.1 394, 6.9 20, 10.9
Extracorporeal membrane oxygenation
(ECMO) (n, %) 85, 1.5 63, 1.1 22, 12.0 <0.001
Mechanical ventilation (n, %) 269, 4.6 236, 4.2 33, 17.9 <0.001
Intra-aortic balloon pump (IABP) (n, %) 1385, 23.7 1318, 23.2 67, 36.4 <0.001
Dialysis or continuous veno-venous
ultrafiltration (n, %) 126, 2.2 112, 2.0 14, 7.6 <0.001
Feeding tube (n, %) 81, 1.4 71, 1.3 10, 5.4 <0.001
Central venous pressure
higher than 15 mmHg (n, %) 1343, 22.9 1282, 22.6 61, 33.2 0.001
Creatinine (mg/dL) (mean± sd) 1.5± 0.8 1.5± 0.7 1.6± 1.1 0.004
Albumin (g/dL) (mean± sd) 3.4± 0.6 3.4± 0.6 3.2± 0.7 <0.001
Device strategy (n, %) Group 1 1289, 22.0 1246, 22.0 43, 23.4 0.008
Group 2 3019, 51.6 2943, 51.9 76, 41.3
Group 3 1548, 26.4 1483, 26.1 65, 35.3
INTERMACS profile (n, %) 1 698, 11.9 617, 10.9 81, 44.0 <0.001
2 2191, 37.4 2123, 37.4 68, 37.0
3 1729, 29.5 1707, 30.1 22, 12.0
4-7 1238, 21.1 1225, 21.6 13, 7.1
Elixhauser comorbidity index (mean± sd) 3.2± 1.5 3.2± 1.5 2.6± 1.4 <0.001
Previous cardiac operation (n, %) 2071, 35.4 2000, 35.3 71, 38.6 0.395
Total bilirubin (mg/dL) (mean± sd) 1.3± 1.5 1.3± 1.4 2.4± 3.0 <0.001
Diastolic blood pressure (mean± sd) 63.9± 11.5 63.9± 11.5 62.0± 11.7 0.02
Hemoglobin (g/dL) (mean± sd) 11.3± 2.0 11.4± 2.0 10.7± 2.1 <0.001
Table 3.3: Estimation of the difference in restricted mean lifetime (days) up to 365
days between BiVAD and LVAD.
δ BiVAD LVAD
Method δ̂ ŜE(δ̂) µ̂1 ŜE(µ̂1) µ̂0 ŜE(µ̂0) P-value
Nelson-Aalen −135.7 17.2 176.7 17.3 312.4 1.5 <0.001
IPTW −125.3 21.9 186.6 22.0 311.8 1.5 <0.001
DIPW −125.0 21.9 186.9 22.0 311.9 1.5 <0.001
Proposed −87.1 25.6 222.8 25.5 309.9 1.9 <0.001
ment groups and their differences. The proposed method yields a larger estimate for
43
BiVAD and smaller estimate for LVAD, and hence smaller absolute difference between
the two groups, compared to the other methods. This seems reasonable because that
the patients in BiVAD are more ill than those in LVAD; thus, failing to adjust for
the imbalances will overestimate the LVAD and underestimate the BiVAD. Regarding
the standard errors, the proposed method does not show improvement compared to
the DIPW method. One possible reason is that we did not estimate the standard
error accurately, which is also a concern in our simulation study (Table 3.1). Recent
work by Li and Ding (2019) introduced the concepts “S-optimal” and “C-optimal”,
which indicated the optimality based on the uncertainty of the sampling distribution
and estimated distribution, respectively. According to the definitions, our proposed
estimators are S-optimal and may differ with the C-optimal estimators.
3.6 Discussion
In this chapter, we propose an augmented double inverse weighted method to
estimate the difference in restricted mean lifetime between groups had no patients
received heart transplant. We incorporate two types of inverse weighting methods
into one single weighting framework to build an estimator and further improve its
efficiency by the augmentation strategy. The asymptotic properties of the proposed
estimator are heuristically proved, and the performance of the proposed methods
in finite samples is shown by simulation. The proposed method is applied to the
INTERMACS cardiac surgery data.
The proposed method allows the clinical analysts to compare restricted mean life-
time in observational study without modeling the complicated relationship between
the outcome and patient covariates. In many cases, the clinicians know much bet-
ter about treatment decision than the relationships between outcomes and patient
covariates. The consistency of the proposed estimator requires correct modeling of
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treatment assignment and dependent censoring. If the relationship between patien-
t covariates and the treatment assignment or dependent censoring is not clear, the
proposed method may not be a good choice. In that case, it may be a better choice
to model the outcome directly if they have good knowledge about the outcome.
We treat the heart transplant as censoring and ignore the information after the
initiation of the heart transplant. There are other strategies which can be used to
deal with such problems. For instance, the heart transplant can be treated as a
secondary treatment and then handled using a marginal structural Cox model that
was proposed by Zhang and Wang (2012). This method would let us gain more
efficiency. However, we did not consider this strategy because the effect of heart
transplant is not specified; moreover, the further efficiency gain may not be sufficiently
large because the percentage of patients receiving heart transplants is small. Another
method is to consider the heart transplant as a time-varying covariate and use an
outcome model to estimate the treatment effect. This method is not applicable in




Methods for Estimating More Meaningful Causal
Treatment Effects as Opposed to The Average
Treatment Effect
4.1 Introduction
In Chapter III, we estimated the average treatment effect (ATE), where the av-
erage was calculated over the whole population. Although the ATE is a popular
estimand in medical research, it is not always the most clinically meaningful quantity
of interest. In Section 3.5, we showed that the patient characteristics vary between
two groups (Table 3.2). Figure 4.1 shows that the discrepancy of the distributions of
the probability of receiving BiVAD between groups. Compared to BiVAD group, a
higher percentage of LVAD patients had a probability of receiving BiVAD close to 0,
and a much smaller percentage of LVAD patients had probability of receiving BiVAD
larger than 0.15. In practice, not all patients can receive either BiVAD or LVAD.
For example, the very sick patients may only receive the BiVAD, while healthier pa-
tients are more likely to receive the LVAD. When doctors compare BiVAD and LVAD,
they may want to exclude the patients who are unlikely to receive either treatmen-
t or control, and mainly focus on the patients who may receive either. Therefore,
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in this chapter, we are interested in estimating the average treatment effect on the
matched population (ATM), which is the treatment-specific difference in potential
restricted mean lifetimes on the matched population, had no patients received heart
transplants. Here the matched population means the population that can be matched
between treatment and control using propensity scores (PS).
Figure 4.1: Distribution of PS by treatment groups
According to the definition of ATM, we know that the PS matching is a natural
method for estimating the ATM. However, PS matching has some drawbacks in prac-
tice. First, it is challenging to estimate the variances of the PS matching estimators.
To our best knowledge, the asymptotic properties of the PS matching methods have
not yet been well studied. As an alternative, the bootstrap method has been used
for estimating the standard errors of PS matching estimators. However, Abadie and
Imbens (2008) showed that bootstrap standard errors are generally not valid for the
matching estimators. Abadie and Imbens (2006) proposed a method for estimating
standard errors for nearest neighbor matching with replacement, but this matching
approach is infrequently used in medical research. How to calculate standard er-
rors for the popular matching methods, including one-to-one PS matching without
replacement and optimal matching, remains unclear. Secondly, we always need to
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subjectively choose a matching algorithm or tuning parameters like the caliper size
for the caliper matching, in order to achieve the best balance between groups. How-
ever, the criteria for whether achieving the best balances is often vague. Thirdly, it is
difficult to develop methods to improve efficiency of PS matching. In Chapter II, we
proposed methods to improve the efficiency of PS matching, but they lacked rigorous
theoretical derivation.
Unlike PS matching, the inverse probability weighting (IPW) methods have a rig-
orous theoretical framework, which can be used to derive the asymptotic properties
and improve the efficiency of estimation using strategies like augmentation. How-
ever, the IPW is generally used to estimate the ATE instead of the ATM. Li and
Greene (2013) proposed a PS weighting method called the matching weight (MW)
method, which is an analogue to the one-to-one PS caliper matching method with-
out replacement. They showed that compared to PS matching, the MW method has
an asymptotically identical estimand but better variance calculation and efficiency
of estimation. The non-stabilized IPW weights are the inverse of the probability of
being assigned to the treatment or control, while the matching weight is defined as a
product of the usual non-stabilized IPW weight and a term min(ei, 1 − ei), i.e. the
matching weight wmwi =
min(ei,1−ei)
Aiei+(1−Ai)(1−ei) where ei is the conditional probability of
being assigned to treatment and Ai is the indicator of being assigned to treatment
for subject i. Intuitively, suppose there are k patients whose propensity scores are
close to e∗, then approximately ke∗ patients would be assigned to the treatment,
and k(1 − e∗) would be assigned to the control. If e∗ < 0.5, fewer patients would
be assigned to the treatment and more patients would be assigned to the control,
all treated patients can be matched while only a subset of control patients can be
matched. Therefore, the probability of being matched for treated patients is about
1, and the probability of being matched for control is about e∗/(1 − e∗). As we can
see, these two probabilities are exactly the wmwi conditional on Ai and ei. In other
48
words, intuitively the wmwi can be viewed as the probability of being matched. Please
note that the one-to-one PS caliper matching discards the patients that cannot be
matched, while the MW method keeps all the patients and only down-weights some
patients whose PSs are close to 0 or 1.
Li and Greene (2013) proposed the MW method for continuous outcomes and
discussed the possibility of extending to binary outcomes. However, how to apply
the MW method for causal inference for survival outcomes and further improve the
efficiency of estimation has not been studied. In this chapter, motivated by the same
application as in Chapter III, we adopt the MW method for estimating the treatment-
specific difference in potential restricted mean lifetimes for the matched population,
had no patients received heart transplants. Then we propose augmentation methods
to improve the efficiency of estimation.
The remainder of the chapter is organized as follows: in Section 4.2, we describe
the notation. In Section 4.3, we propose the augmented MW methods. Then we e-
valuate the performance of the proposed methods using a simulation study in Section
4.4. In Section 4.5, we apply our methods to analyze the cardiac surgery data ob-
tained from the Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS). Finally, we conclude and discuss in Section 4.6.
4.2 Notations
The notations are the same as in Chapter III. We let A denote treatment groups
that are not randomized (A = 0 control, A = 1 treatment). We let T denote the
survival time without heart transplant and C denote the dependent censoring (heart
transplant). U = T ∧ C denotes the observation time, and ∆ = I(T ≤ C) is the
indicator for observing the death time. We let Z denote baseline covariate vector,
and Z(t) represent the time-dependent covariate at time t. We let Z̃(t) = {Z(u);u ∈
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[0, t)} denote the history of the baseline and time-dependent covariates up to time t.
We denote the observed event process and at-risk processes by Ni(t) = I(Ui ≤ t,∆ =
1) and Yi(t) = I(Ui ≥ t), i = 1, ..., n, respectively.
We define the parameter of interest by using the potential outcome framework
which was studied by Rubin (1974, 1978, 1980). Let T k (k = 0,1) denote the potential
(or counterfactual) lifetime for a randomly selected subject from the population if,
possibly contrary to fact, s/he was assigned to group k, and not censored by heart
transplant. We assume that there are no unmeasured baseline confounders. We




ξ−1P{t ≤ Ui < t+ ξ,∆i = 0|Ui ≥ t, Ai, Z̃i(t), Ti}
= lim
ξ→0
ξ−1P{t ≤ Ui < t+ ξ,∆i = 0|Ui ≥ t, Ai, Z̃i(t)}.
The estimand of interest δ is the difference in restricted mean lifetime up to time
L between two treatment groups on the matched population, had no patients re-
ceived heart transplants. Let µk denote the restricted mean lifetime on the matched
population in group k and Sk(t) = P{T k > t|A = 1}, then
δ = µ1 − µ0












4.3.1 Matching Weight Method
Li and Greene (2013) defined the matching weight for patient i as
wmwi =
min(ei, 1− ei)
Aiei + (1− Ai)(1− ei)
, (4.1)
where ei = Pr(Ai = 1|Zi). Using the same double inverse weighting method as in
Chapter III, we combine the IPTW and IPCW to develop the double inverse weighted







{Aiêi + (1− Ai)(1− êi)}pci(γ̂, t)
]
= 0, (4.2)
where Aik = I(Ai = k), and Ψ = E{min(ei, 1− ei)}. êi ≡ ei(θ̂) estimates ei through
a model with parameter θ, and pci(γ̂, t) estimates informally the probability of not
being censored conditional on {Ai, Zi, Z̃i(t)} through a model with parameter γ. By
















where wmwi (θ̂) =
min(ei(θ̂),1−ei(θ̂))
Aiei(θ̂)+(1−Ai)(1−ei(θ̂))
and wci (γ̂, u) = I(Ci > t)/p
c
i(γ̂, t).
4.3.2 Proposed Augmented MW Methods
Starting from the MW estimator for Λk(t) that we derived, we propose augmen-
tation methods to improve its efficiency. Similar with Equation (3.2), we propose the
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{Aiêi + (1− Ai)(1− êi)}pci(γ̂, t)






where êik estimates P (Aik = 1|Zi) and hk(t, Zi) is an arbitrary function of baseline
covariate Zi at time t. We consider two augmentation strategies. The first strategy
is the augmentation method proposed in Chapter III; that is, we consider a subclass








{Aiêi + (1− Ai)(1− êi)}pci(γ̂, t)






Then we use the ordinary least square (OLS) method to obtain β̂optk (t). Specifically,








{Aiêi + (1− Ai)(1− êi)}pci(γ̂, t)
]
.
As we don’t know dΛk(t), we substitute it with dΛ̂
mw












Then the optimal βk(t) can be estimated by β̂
opt
k (t)dt = (C
TC)−1CTO. Plugging
β̂optk (t)dt into Equation (4.4) and solving the equation, the augmented double inverse
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Alternatively, motivated by Zhang and Schaubel (2012a) and Zhang and Schaubel
(2012b), we consider using the Cox model for augmentation. The augmented double

















where Λ̂ik(u) and dΛ̂ik(u) were estimated through a Cox model.
4.4 Simulation Study
We perform a simulation study to evaluate performance of the proposed methods.
The reported results are based on 5000 Monte Carlo data sets. In each data set, the
sample size n is 500. We use the same simulation settings and scenarios as in Chapter
III; please refer to Section 3.4 for the detailed information of the simulation design.
In our simulation, we use correct treatment assignment model and censoring model
for the estimation of restricted mean lifetime. Specifically, we use treatment assign-
ment model
logit{P (Ai = 1|Zi)} = β1Z1 + β2Z2,
and Cox model for censoring
λc(t|Zi, Zi(t), Ai) = λc0(t)exp{γ1Z3,i + γ2Zi(t)},
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where λc(t|Zi, Zi(t), Ai) is the conditional hazard for censoring. For the proposed
methods, when we use the OLS augmentation method, we let gk(Z, u) be a basis
function including intercept and linear forms of all baseline covariates, i.e. gk(Z, u) =
(1, Z1, Z2, Z3)
T . When we use the Cox augmentation method, we use the following
model to calculate Λ̂ik(t) and dΛ̂ik(t)
λ(t|Zi, Zi(t), Ai) = λ0(t)exp{η1Z1,i + η2Z2,i + η3Z3,i}.
We estimate standard errors of estimators via the bootstrap approach.
We evaluate the performance of the proposed methods, together with the methods
described in Chapter III, including the Nelson-Aalen, IPTW and DIPW methods.
The simulation results are summarized in Table 4.1.
Table 4.1: Estimation of the difference in restricted mean lifetime between treatment
and control. The results are based on 5000 Monte Carlo datasets. Sample
size n = 500.
δ̂ µ̂1 µ̂0
Method Bias ESD ASE CP RE Bias ESD ASE CP Bias ESD ASE CP
Scenario 1
NA −0.456 0.053 0.053 0.000 −0.175 0.039 0.038 0.004 0.281 0.036 0.036 0.000
IPTW −0.054 0.077 0.084 0.900 0.015 0.047 0.049 0.954 0.069 0.070 0.067 0.754
DIPW −0.022 0.087 0.091 0.942 −0.001 0.051 0.052 0.961 0.021 0.078 0.073 0.908
MW 0.001 0.080 0.078 0.941 1 0.040 0.048 0.045 0.818 0.039 0.069 0.062 0.854
Proposed (OLS) 0.002 0.076 0.073 0.947 1.11 0.041 0.046 0.045 0.810 0.039 0.067 0.061 0.858
Proposed (Cox) 0.002 0.074 0.080 0.965 1.17 0.039 0.045 0.048 0.852 0.038 0.067 0.062 0.852
Scenario 2
NA −0.318 0.046 0.046 0.000 −0.114 0.034 0.033 0.071 0.205 0.032 0.032 0.000
IPTW −0.051 0.074 0.072 0.847 0.016 0.039 0.040 0.942 0.066 0.067 0.059 0.682
DIPW −0.025 0.091 0.083 0.905 −0.002 0.044 0.044 0.954 0.023 0.083 0.070 0.864
MW −0.010 0.079 0.073 0.934 1 0.022 0.042 0.040 0.880 0.032 0.069 0.060 0.864
Proposed (OLS) −0.009 0.078 0.072 0.936 1.03 0.023 0.041 0.040 0.881 0.031 0.068 0.061 0.873
Proposed (Cox) −0.010 0.077 0.079 0.960 1.05 0.022 0.041 0.044 0.920 0.032 0.068 0.062 0.884
Scenario 3
NA −0.430 0.048 0.047 0.000 −0.156 0.033 0.033 0.004 0.274 0.034 0.034 0.000
IPTW −0.064 0.069 0.076 0.853 0.021 0.045 0.047 0.946 0.085 0.060 0.058 0.610
DIPW −0.026 0.085 0.085 0.930 −0.001 0.050 0.050 0.956 0.025 0.075 0.068 0.883
MW −0.003 0.076 0.072 0.943 1 0.025 0.045 0.042 0.877 0.028 0.066 0.058 0.880
Proposed (OLS) −0.002 0.072 0.068 0.939 1.12 0.026 0.043 0.041 0.878 0.027 0.065 0.057 0.882
Proposed (Cox) −0.003 0.071 0.077 0.968 1.15 0.025 0.042 0.045 0.915 0.028 0.065 0.059 0.900
Bias:Monte Carlo bias. ESD: Monte Carlo standard deviation. ASE: Monte Carlo
average of estimated standard errors. CP: coverage probability of nominal 95% Wald
confidence intervals. RE: Monte Carlo mean squared error for the MW estimator
divided by that for the indicated estimator
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In all scenarios, the biases of δ̂ for the MW and proposed methods are negligible
compared to the other methods. The 95% coverage probabilities appear to achieve the
nominal level. There are biases for µ̂1 and µ̂0 from the MW and proposed methods.
This is because the true µ1 and µ0 values that we used to calculate biases are the
expectation of potential outcomes for the whole population. However, here the µ̂1
and µ̂0 estimated by the MW and proposed methods are for a subpopulation, that
is the patients who can be matched between two groups. Hence, it is actually unfair
to compare the biases of group-level estimates between MW methods and usual IPW
methods (IPTW and DIPW), because they estimate different estimands.
Next, we compare the efficiency of the methods. As we show in Chapter III, the
simple IPW estimators including IPTW and DIPW reduce bias but lose efficiency.
The MW method is also a simple double inverse weighted estimator, but compared to
DIPW method, the variances are much smaller. As we stated in Section 4.1, the MW
method reduces variances because it down-weights some of the patients. The resulting
weighted population is more homogeneous compared to the weighted population by
the usual IPW methods.
In Table 4.1, we also see that the proposed augmentation methods reduce the
variance of the MW estimators. We use relative efficiency to quantify the difference
in efficiency between the MW and the proposed methods. The relative efficiency is
defined as the ratio of mean squared errors for the MW method and the proposed
methods. In three scenarios, for proposed OLS methods, the relative efficiencies are
between 1.03 and 1.12 for δ̂. For the proposed Cox methods, the relative efficiencies
are even larger, which are between 1.05 and 1.17 for δ̂. This results suggest that
the proposed methods successfully improve efficiency of MW estimators in different
situations of outcome distributions and generating models.
Furthermore, we see that the proposed Cox method has larger efficiency gains in
Scenario 1 and 3 compared to Scenario 2. This may be because that we generate
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survival time from Cox models in Scenario 1 and 3, but from an accelerated failure
time (AFT) model in Scenario 2. Although the analysis outcome model we use in
Scenario 2 is incorrect, the proposed Cox method still shows some efficiency gain.
4.5 Application
We apply the proposed method to the same application data as in Chapter III. The
5,856 advanced heart failure patients received either LVAD or BiVAD implantations.
Of these patients, 5,672 (96.9%) patients received LVAD and 184 (3.1%) patients
received BiVAD. We showed the baseline imbalances between the two groups in Table
3.2. As in Chapter III, we consider BiVAD as the treatment and LVAD as the control.
We are interested in estimating treatment-specific difference in potential restricted
mean lifetimes on the matched population, had no patients received heart transplants.
The proposed methods show smaller estimates of the differences between BiVAD and
Table 4.2: Estimation of the difference in restricted mean lifetime (days) up to 365
days between BiVAD and LVAD.
δ BiVAD LVAD
Method δ̂ ŜE(δ̂) µ̂1 ŜE(µ̂1) µ̂0 ŜE(µ̂0) P-value
Nelson-Aalen −135.7 17.2 176.7 17.3 312.4 1.5 <0.001
IPTW −125.3 21.9 186.6 22.0 311.8 1.5 <0.001
DIPW −125.0 21.9 186.9 22.0 311.9 1.5 <0.001
MW −117.8 17.1 177.1 17.3 294.9 4.0 <0.001
Proposed (OLS) −119.2 17.9 184.7 17.1 303.9 5.5 <0.001
Proposed (Cox) −92.0 16.4 202.5 16.5 294.5 3.7 <0.001
LVAD compared to the DIPW method. The MW shows smaller standard errors than
the DIPW method. The proposed Cox augmentation method has smaller standard
errors than the MW method.
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4.6 Discussion
In this chapter, we discuss the clinically meaningful estimand and then propose
methods to estimate that estimand. Specifically, we propose an augmented double
inverse MW method to estimate the difference in the restricted mean lifetime on the
matched population between groups. We first develop an MW estimator and then
propose augmentation strategies to improve the efficiency. We show the performance
of the proposed methods in finite sample using simulation. The proposed methods
are then applied to INTERMACS cardiac surgery data.
The MW method is an analog to the one-to-one caliper matching without replace-
ment, but it has better properties of variance estimation and efficiency improvement.
Li and Greene (2013) showed the MW method was more efficient than the one-to-one
caliper matching without replacement in their continuous outcome setting. Beside
one-to-one caliper matching, there are many other types of PS matching methods,
such as matching with replacement, nearest neighbor matching, optimal matching,
and many-to-one matching. It would be interesting to compare the performance of
the MW method with these types of matching. We can also apply the doubly robust
PS matching method proposed in Chapter II for survival outcomes and compare the
performance with the proposed OLS and Cox methods.
Our simulation results show that the MW method is more efficient than DIPW
method. As we know, the DIPW method use the usual IPW weight which is the
inverse of probability of being assigned to one group. The usual IPW weights can be
very large when the propensity scores are small, which greatly increase the variability
of the estimation and make the estimation unstable. But the MW method down-
weights the patients with extreme propensity scores and control the variance inflation.
This is why we see the MW method is generally more efficient than DIPW method.
We use the bootstrap approach to calculate standard errors for the MW and
proposed augmented estimators. We can also study the asymptotic properties and
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develop the closed form of standard errors, because the MW method provides a good





Appendix for Chapter II
A.1 Simulation Results for Matching with Replacement
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Table A.1: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use matching with replacement. The results are based on 1000 Monte Carlo data
sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5






PS Model 1 0.001 0.120 0.031 0.158 0.031 0.158 0.010 0.126 0.010 0.126
PS Model 2 −0.002 0.111 0.005 0.132 0.005 0.132 0.000 0.116 0.000 0.116
PS Model 3 0.000 0.114 1.158 0.148 1.158 0.148 −0.006 0.130 −0.008 0.130
PS Model 4 0.001 0.119 0.032 0.143 0.032 0.143 0.011 0.125 0.011 0.125




PS Model 1 0.003 0.128 −0.060 0.224 0.039 0.193 0.014 0.149 0.014 0.149
PS Model 2 −0.003 0.111 0.369 0.315 0.328 0.153 0.007 0.120 −0.007 0.120
PS Model 3 −0.001 0.106 1.325 0.273 1.247 0.140 0.003 0.123 −0.011 0.124
PS Model 4 0.000 0.129 −0.038 0.217 0.037 0.181 0.011 0.148 0.010 0.148





PS Model 1 0.002 0.125 0.082 0.196 0.139 0.177 0.034 0.140 0.034 0.140
PS Model 2 −0.001 0.108 0.173 0.185 0.235 0.139 0.010 0.116 0.004 0.116
PS Model 3 −0.001 0.113 1.168 0.147 1.164 0.147 −0.005 0.129 −0.008 0.129
PS Model 4 0.000 0.124 0.091 0.184 0.138 0.163 0.033 0.139 0.033 0.139
PS Model 5 0.002 0.124 0.131 0.182 0.171 0.164 0.038 0.139 0.038 0.139
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Table A.2: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use matching with replacement. The results are based
on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5






PS Model 1 0.094 0.877 0.163 0.952 0.147 0.921 0.105 0.897 0.105 0.898
PS Model 2 0.099 0.928 0.170 0.987 0.153 0.976 0.110 0.939 0.110 0.939
PS Model 3 0.095 0.902 0.157 0.000 0.143 0.000 0.118 0.924 0.118 0.916
PS Model 4 0.094 0.882 0.163 0.970 0.147 0.941 0.105 0.902 0.105 0.902




PS Model 1 0.088 0.819 0.161 0.823 0.146 0.847 0.103 0.834 0.103 0.831
PS Model 2 0.096 0.906 0.155 0.427 0.157 0.438 0.111 0.931 0.112 0.926
PS Model 3 0.099 0.939 0.152 0.000 0.151 0.000 0.121 0.944 0.121 0.943
PS Model 4 0.088 0.812 0.161 0.851 0.146 0.877 0.103 0.822 0.103 0.821





PS Model 1 0.088 0.833 0.158 0.849 0.143 0.783 0.101 0.837 0.101 0.839
PS Model 2 0.088 0.897 0.155 0.767 0.145 0.636 0.103 0.922 0.103 0.919
PS Model 3 0.094 0.901 0.156 0.000 0.142 0.000 0.116 0.921 0.116 0.916
PS Model 4 0.087 0.839 0.158 0.867 0.144 0.809 0.101 0.836 0.101 0.836
PS Model 5 0.087 0.834 0.157 0.828 0.143 0.743 0.101 0.825 0.101 0.824
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Table A.3: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use matching with replacement. The results are based on 1000 Monte Carlo data sets
with number of hospitals equals to 30 and hospital size equals to 100.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5






PS Model 1 0.002 0.115 0.031 0.147 0.031 0.147 0.013 0.121 0.013 0.121
PS Model 2 0.000 0.108 0.007 0.129 0.007 0.129 0.003 0.112 0.003 0.112
PS Model 3 0.000 0.110 1.159 0.148 1.159 0.148 −0.005 0.126 −0.008 0.126
PS Model 4 0.001 0.116 0.029 0.138 0.029 0.138 0.011 0.121 0.011 0.121




PS Model 1 0.004 0.124 −0.051 0.220 0.044 0.187 0.017 0.146 0.017 0.146
PS Model 2 0.000 0.109 0.405 0.292 0.340 0.154 0.013 0.119 −0.002 0.119
PS Model 3 −0.001 0.104 1.349 0.258 1.249 0.143 0.004 0.121 −0.012 0.121
PS Model 4 0.004 0.122 −0.027 0.205 0.045 0.174 0.019 0.145 0.019 0.145





PS Model 1 0.003 0.121 0.090 0.189 0.149 0.167 0.038 0.137 0.039 0.137
PS Model 2 0.001 0.104 0.202 0.181 0.254 0.136 0.015 0.113 0.008 0.113
PS Model 3 0.000 0.110 1.171 0.149 1.166 0.148 −0.004 0.126 −0.008 0.126
PS Model 4 0.003 0.121 0.099 0.183 0.148 0.160 0.039 0.138 0.039 0.138
PS Model 5 0.003 0.121 0.137 0.182 0.180 0.160 0.041 0.137 0.041 0.137
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Table A.4: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use matching with replacement. The results are based
on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5






PS Model 1 0.094 0.897 0.163 0.970 0.146 0.942 0.105 0.920 0.105 0.920
PS Model 2 0.100 0.930 0.171 0.992 0.153 0.982 0.111 0.954 0.111 0.954
PS Model 3 0.095 0.902 0.157 0.000 0.143 0.000 0.118 0.935 0.118 0.936
PS Model 4 0.094 0.892 0.163 0.984 0.146 0.967 0.105 0.917 0.105 0.917




PS Model 1 0.088 0.848 0.160 0.847 0.146 0.870 0.103 0.830 0.103 0.830
PS Model 2 0.096 0.904 0.154 0.366 0.157 0.421 0.111 0.929 0.112 0.936
PS Model 3 0.099 0.935 0.152 0.000 0.152 0.000 0.121 0.949 0.122 0.945
PS Model 4 0.088 0.847 0.161 0.875 0.146 0.890 0.103 0.828 0.103 0.829





PS Model 1 0.087 0.848 0.158 0.877 0.143 0.774 0.101 0.835 0.101 0.835
PS Model 2 0.088 0.897 0.155 0.719 0.145 0.594 0.103 0.929 0.103 0.925
PS Model 3 0.094 0.909 0.156 0.000 0.143 0.000 0.117 0.932 0.117 0.933
PS Model 4 0.087 0.843 0.158 0.860 0.143 0.796 0.101 0.835 0.101 0.838
PS Model 5 0.087 0.838 0.157 0.816 0.143 0.725 0.101 0.839 0.101 0.838
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Table A.5: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use matching with replacement. The results are based on 1000 Monte Carlo data sets
with number of hospitals equals to 30 and hospital size follows uniform distribution U(30,170).
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5






PS Model 1 0.001 0.120 0.031 0.158 0.031 0.158 0.010 0.126 0.010 0.126
PS Model 2 −0.002 0.111 0.005 0.132 0.005 0.132 0.000 0.116 0.000 0.116
PS Model 3 0.000 0.114 1.158 0.148 1.158 0.148 −0.006 0.130 −0.008 0.130
PS Model 4 0.001 0.119 0.032 0.143 0.032 0.143 0.011 0.125 0.011 0.125




PS Model 1 0.003 0.128 −0.060 0.224 0.039 0.193 0.014 0.149 0.014 0.149
PS Model 2 −0.003 0.111 0.369 0.315 0.328 0.153 0.007 0.120 −0.007 0.120
PS Model 3 −0.001 0.106 1.325 0.273 1.247 0.140 0.003 0.123 −0.011 0.124
PS Model 4 0.000 0.129 −0.038 0.217 0.037 0.181 0.011 0.148 0.010 0.148





PS Model 1 0.002 0.125 0.082 0.196 0.139 0.177 0.034 0.140 0.034 0.140
PS Model 2 −0.001 0.108 0.173 0.185 0.235 0.139 0.010 0.116 0.004 0.116
PS Model 3 −0.001 0.113 1.168 0.147 1.164 0.147 −0.005 0.129 −0.008 0.129
PS Model 4 0.000 0.124 0.091 0.184 0.138 0.163 0.033 0.139 0.033 0.139
PS Model 5 0.002 0.124 0.131 0.182 0.171 0.164 0.038 0.139 0.038 0.139
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Table A.6: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use matching with replacement. The results are based
on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size follows uniform distribution
U(30,170).
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5






PS Model 1 0.094 0.877 0.163 0.952 0.147 0.921 0.105 0.897 0.105 0.898
PS Model 2 0.099 0.928 0.170 0.987 0.153 0.976 0.110 0.939 0.110 0.939
PS Model 3 0.095 0.902 0.157 0.000 0.143 0.000 0.118 0.924 0.118 0.916
PS Model 4 0.094 0.882 0.163 0.970 0.147 0.941 0.105 0.902 0.105 0.902




PS Model 1 0.088 0.819 0.161 0.823 0.146 0.847 0.103 0.834 0.103 0.831
PS Model 2 0.096 0.906 0.155 0.427 0.157 0.438 0.111 0.931 0.112 0.926
PS Model 3 0.099 0.939 0.152 0.000 0.151 0.000 0.121 0.944 0.121 0.943
PS Model 4 0.088 0.812 0.161 0.851 0.146 0.877 0.103 0.822 0.103 0.821





PS Model 1 0.088 0.833 0.158 0.849 0.143 0.783 0.101 0.837 0.101 0.839
PS Model 2 0.088 0.897 0.155 0.767 0.145 0.636 0.103 0.922 0.103 0.919
PS Model 3 0.094 0.901 0.156 0.000 0.142 0.000 0.116 0.921 0.116 0.916
PS Model 4 0.087 0.839 0.158 0.867 0.144 0.809 0.101 0.836 0.101 0.836
PS Model 5 0.087 0.834 0.157 0.828 0.143 0.743 0.101 0.825 0.101 0.824
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A.2 Simulation Results for Modified Matching with Replace-
ment
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Table A.7: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use modified matching with replacement. The results are based on 1000 Monte Carlo
data sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5
Bias MCSD Bias MCSD Bias MCSD Bias MCSD Bias MCSD
Outcome Regression
Only







PS Model 1 −0.002 0.224 0.010 0.286 0.010 0.286 0.003 0.231 0.003 0.231
PS Model 2 −0.001 0.238 0.005 0.278 0.005 0.278 0.003 0.248 0.003 0.248
PS Model 3 −0.001 0.198 1.186 0.246 1.186 0.246 0.001 0.227 −0.009 0.228
PS Model 4 −0.001 0.224 0.012 0.260 0.012 0.260 0.005 0.232 0.005 0.232




PS Model 1 0.006 0.184 −0.148 0.259 −0.142 0.256 0.007 0.212 0.016 0.212
PS Model 2 0.004 0.178 0.417 0.333 0.253 0.219 0.043 0.193 −0.002 0.195
PS Model 3 0.004 0.175 1.359 0.314 1.266 0.230 0.041 0.206 −0.002 0.207
PS Model 4 0.005 0.184 −0.088 0.231 −0.140 0.222 0.014 0.208 0.013 0.208





PS Model 1 0.005 0.180 −0.065 0.249 −0.046 0.244 0.017 0.199 0.017 0.200
PS Model 2 0.003 0.177 0.388 0.310 0.303 0.213 0.044 0.191 0.004 0.193
PS Model 3 0.003 0.174 1.354 0.287 1.311 0.224 0.023 0.202 −0.016 0.204
PS Model 4 0.003 0.180 −0.025 0.216 −0.048 0.210 0.022 0.197 0.017 0.197
PS Model 5 0.005 0.180 0.069 0.217 0.030 0.210 0.015 0.200 0.015 0.199
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Table A.8: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use matching with replacement. The results are based
on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5







PS Model 1 −0.002 0.224 0.010 0.286 0.010 0.286 0.003 0.231 0.003 0.231
PS Model 2 −0.001 0.238 0.005 0.278 0.005 0.278 0.003 0.248 0.003 0.248
PS Model 3 −0.001 0.198 1.186 0.246 1.186 0.246 0.001 0.227 −0.009 0.228
PS Model 4 −0.001 0.224 0.012 0.260 0.012 0.260 0.005 0.232 0.005 0.232




PS Model 1 0.006 0.184 −0.148 0.259 −0.142 0.256 0.007 0.212 0.016 0.212
PS Model 2 0.004 0.178 0.417 0.333 0.253 0.219 0.043 0.193 −0.002 0.195
PS Model 3 0.004 0.175 1.359 0.314 1.266 0.230 0.041 0.206 −0.002 0.207
PS Model 4 0.005 0.184 −0.088 0.231 −0.140 0.222 0.014 0.208 0.013 0.208





PS Model 1 0.005 0.180 −0.065 0.249 −0.046 0.244 0.017 0.199 0.017 0.200
PS Model 2 0.003 0.177 0.388 0.310 0.303 0.213 0.044 0.191 0.004 0.193
PS Model 3 0.003 0.174 1.354 0.287 1.311 0.224 0.023 0.202 −0.016 0.204
PS Model 4 0.003 0.180 −0.025 0.216 −0.048 0.210 0.022 0.197 0.017 0.197
PS Model 5 0.005 0.180 0.069 0.217 0.030 0.210 0.015 0.200 0.015 0.199
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Table A.9: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use modified matching with replacement. The results are based on 1000 Monte Carlo
data sets with number of hospitals equals to 30 and hospital size equals to 100.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5







PS Model 1 0.000 0.100 0.017 0.127 0.017 0.127 0.004 0.104 0.004 0.104
PS Model 2 −0.002 0.101 0.007 0.118 0.007 0.118 0.001 0.104 0.001 0.104
PS Model 3 0.000 0.095 1.181 0.128 1.181 0.128 0.000 0.106 −0.003 0.106
PS Model 4 −0.002 0.099 0.013 0.109 0.013 0.109 0.002 0.102 0.002 0.102




PS Model 1 0.002 0.093 −0.035 0.154 −0.083 0.140 0.008 0.110 0.010 0.110
PS Model 2 0.001 0.093 0.409 0.277 0.210 0.125 0.006 0.099 −0.008 0.099
PS Model 3 0.000 0.090 1.351 0.249 1.240 0.130 0.005 0.104 −0.009 0.104
PS Model 4 0.001 0.095 −0.013 0.141 −0.083 0.123 0.008 0.111 0.009 0.111





PS Model 1 0.002 0.092 0.092 0.132 0.096 0.124 0.016 0.101 0.014 0.101
PS Model 2 0.000 0.092 0.373 0.232 0.338 0.115 0.018 0.098 0.007 0.098
PS Model 3 0.000 0.090 1.350 0.211 1.311 0.134 −0.014 0.103 −0.026 0.103
PS Model 4 0.000 0.093 0.100 0.117 0.092 0.107 0.013 0.102 0.011 0.102
PS Model 5 −0.001 0.092 0.124 0.116 0.112 0.107 0.011 0.101 0.009 0.101
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Table A.10: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use modified matching with replacement. The results
are based on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size equals to 30.
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5







PS Model 1 0.102 0.953 0.174 0.995 0.157 0.982 0.114 0.970 0.114 0.970
PS Model 2 0.104 0.961 0.176 0.999 0.159 0.995 0.115 0.977 0.115 0.977
PS Model 3 0.097 0.961 0.160 0.000 0.146 0.000 0.120 0.970 0.120 0.971
PS Model 4 0.102 0.960 0.174 1.000 0.157 0.997 0.114 0.971 0.114 0.971




PS Model 1 0.097 0.956 0.165 0.958 0.150 0.928 0.111 0.954 0.111 0.953
PS Model 2 0.095 0.946 0.145 0.339 0.147 0.727 0.107 0.962 0.108 0.964
PS Model 3 0.092 0.948 0.141 0.000 0.141 0.000 0.112 0.969 0.113 0.964
PS Model 4 0.097 0.951 0.165 0.976 0.150 0.957 0.111 0.952 0.111 0.948





PS Model 1 0.095 0.952 0.162 0.958 0.147 0.939 0.108 0.960 0.108 0.959
PS Model 2 0.092 0.951 0.146 0.362 0.142 0.310 0.104 0.963 0.105 0.969
PS Model 3 0.091 0.949 0.144 0.000 0.140 0.000 0.112 0.960 0.112 0.957
PS Model 4 0.095 0.953 0.163 0.969 0.147 0.972 0.108 0.955 0.108 0.957
PS Model 5 0.095 0.951 0.163 0.960 0.147 0.951 0.108 0.959 0.108 0.959
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Table A.11: Monte Carlo bias and standard deviation using the outcome regression method, proposed methods and Li et al
method. For each method, we use 5 PS models (not for the outcome regression method) and 5 outcome models
described in Section 2.3. We use modified matching with replacement. The results are based on 1000 Monte Carlo
data sets with number of hospitals equals to 30 and hospital size follows uniform distribution U(30,170).
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5







PS Model 1 −0.001 0.102 0.016 0.133 0.016 0.133 0.003 0.108 0.003 0.108
PS Model 2 −0.002 0.102 0.007 0.120 0.007 0.120 0.000 0.108 0.000 0.108
PS Model 3 0.000 0.096 1.179 0.126 1.179 0.126 −0.002 0.109 −0.005 0.109
PS Model 4 −0.002 0.101 0.015 0.113 0.015 0.113 0.001 0.106 0.001 0.106




PS Model 1 0.001 0.097 −0.036 0.158 −0.084 0.145 0.008 0.113 0.010 0.113
PS Model 2 0.002 0.095 0.377 0.301 0.205 0.128 0.006 0.101 −0.006 0.101
PS Model 3 0.001 0.092 1.330 0.268 1.238 0.130 0.006 0.108 −0.007 0.108
PS Model 4 0.001 0.097 −0.011 0.142 −0.081 0.125 0.009 0.112 0.010 0.113





PS Model 1 0.000 0.094 0.093 0.137 0.097 0.130 0.012 0.104 0.010 0.104
PS Model 2 0.001 0.093 0.349 0.252 0.336 0.123 0.017 0.101 0.007 0.101
PS Model 3 0.000 0.092 1.331 0.220 1.308 0.134 −0.016 0.107 −0.026 0.107
PS Model 4 0.000 0.094 0.105 0.117 0.098 0.109 0.012 0.102 0.010 0.102
PS Model 5 0.000 0.094 0.129 0.117 0.118 0.109 0.009 0.103 0.008 0.103
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Table A.12: Monte Carlo average of estimated standard errors and coverage probability using the outcome regression method,
proposed methods and Li et al method. For each method, we use 5 PS models (not for the outcome regression
method) and 5 outcome models described in Section 2.3. We use modified matching with replacement. The results
are based on 1000 Monte Carlo data sets with number of hospitals equals to 30 and hospital size follows uniform
distribution U(30,170).
PS Model
Outcome Model 1 Outcome Model 2 Outcome Model 3 Outcome Model 4 Outcome Model 5







PS Model 1 0.102 0.946 0.174 0.988 0.156 0.975 0.114 0.958 0.114 0.958
PS Model 2 0.103 0.955 0.176 0.997 0.158 0.990 0.115 0.964 0.115 0.964
PS Model 3 0.097 0.951 0.160 0.000 0.146 0.000 0.120 0.968 0.120 0.967
PS Model 4 0.102 0.957 0.174 0.998 0.156 0.994 0.114 0.956 0.114 0.956




PS Model 1 0.097 0.949 0.165 0.949 0.150 0.918 0.111 0.940 0.111 0.938
PS Model 2 0.095 0.956 0.145 0.390 0.146 0.743 0.107 0.961 0.108 0.958
PS Model 3 0.092 0.953 0.141 0.000 0.141 0.000 0.112 0.958 0.113 0.958
PS Model 4 0.097 0.947 0.165 0.981 0.150 0.955 0.111 0.944 0.111 0.942





PS Model 1 0.094 0.948 0.162 0.948 0.147 0.936 0.107 0.954 0.107 0.956
PS Model 2 0.092 0.949 0.146 0.405 0.141 0.314 0.104 0.955 0.104 0.961
PS Model 3 0.091 0.954 0.144 0.000 0.140 0.000 0.112 0.959 0.112 0.953
PS Model 4 0.095 0.956 0.162 0.963 0.147 0.959 0.107 0.962 0.107 0.962
PS Model 5 0.094 0.952 0.162 0.947 0.147 0.946 0.107 0.964 0.107 0.962
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APPENDIX B
Appendix for Chapter III
B.1 Asymptotic Properties
We heuristically prove that the estimator that solves Equation (3.2) is consistent
and asymptotically normal.




AikI(Ci ≥ t){dN∗ik(t)− Y ∗ik(t)dΛk(t)}
pik(θ)pci(γ, t)





We define m(t, θ, γ) as
m(t, θ, γ) =
AikI(Ci ≥ t){dN∗ik(t)− Y ∗ik(t)dΛk(t)}
pik(θ)pci(γ, t)




Then the left part of Equation (B.1) is a summation of independent and identically
distributed quantities m(t, θ, γ). The expectation of the first part of m(t, θ, γ) is:
E
[







AikI(Ci ≥ t){dN∗ik(t)− Y ∗ik(t)dΛk(t)}
pik(θ)pci(γ, t)
∣∣∣∣Zi}]








































hk(t, Zi)dt ∗ 0
]
= 0.
Thus, the expectation of m(t, θ, γ) is equal to 0. As m(t, θ, γ) has expectation 0, Λ̂j(t)
is an M-estimator and therefore is consistent and asymptotically normal.
B.2 Generating Censoring and Survival Times




The censoring time C is generated from a Cox model and λc(t|Z(t), Z) = λc0{exp(1.5Z3+
0.3Z(t))}. We assume C is exponentially distributed and λc0(t) = λc = 1.5. To gener-
ate C, we follow the same procedure with generating the survival time T in Scenario
1.
B.2.2 Scenario 1
In the first scenario, the survival time T is generated from a Cox model and
λ(t|Z(t), X) = λ0(t) exp{ηX + βZ(t)}. We assume T is exponentially distributed
and λ0(t) = λ, then then cumulative hazard function








If t < t∗,
Λ(t|Z(t), X) = λ exp(ηX)
t∫
0
exp{0}du = λ exp(ηX)t;
If t ≥ t∗,









= λ exp(ηX){1− exp(β)}t∗ + λ exp(ηX + β)t.
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, if − log(u) ≤ λ exp(ηX)t∗
− log(u)− λ exp(ηX){1− exp(β)}t∗
λ exp(ηX + β)
, if − log(u) > λ exp(ηX)t∗,
where u ∼ U(0, 1).
In this scenario, we let λ = 0.6, η = (−0.5, 1, −1, 1, −0.5) and β = 0.3.
B.2.3 Scenario 2
In the second scenario, the survival time T is generated from an accelerated failure
time (AFT) model. For the time dependent covariate Z(t), Cox (2018) proposed an





where U is the latent baseline survival time.









exp{ηX + 0}ds = exp(ηX)t;
77








= exp(ηX)t∗ + exp(ηX + β)(T − t∗).





, if exp(ηX)U ≤ t∗
U − exp(ηX){1− exp(β)}t∗
exp(ηX + β)
, if exp(ηX)U > t∗.
In this scenario, we let η = (0.2, −0.5, 0.5, −0.5, 0.3) and β = −0.3.
B.2.4 Scenario 3
In the third scenario, the survival time T is generated from a Cox model and we




λ0(u) exp{ηX + βZ(u)}du.



















λ0(u) exp(ηX + β)du
= exp(ηX)Λ0(t
∗) + exp(ηX + β){Λ0(t)− Λ0(t∗)}
= exp(ηX)[1− exp(β)]Λ0(t∗) + exp(ηX + β)Λ0(t).
Hence
Λ0(t) =
Λ(t|Z(t), X)− exp(ηX)[1− exp(β)]Λ0(t∗)
exp(ηX + β)
. (B.3)
The cumulative baseline hazard function for the lognormal distributed T is:







As S(t|Z(t), X) = exp{−Λ(t|Z(t), X)} and S(t|Z(t), X) follows uniform distribution
U(0, 1), we generate T by inversing the cumulative baseline hazard function (B.4),
plugging in the right sides of Equation (B.2) and (B.3) respectively, and replacing























In this scenario, we let η = (0.2, 1, −1, 1, −0.5) and β = 0.3.
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B.3 Practical Implementations
Take the treatment (A = 1) as an example, we show how to implement our method.
Step 1. Fit treatment assignment model
We fit a logistic model with parameter θ for treatment assignment using Z as the
covariates, i.e. logit{P (Ai = 1|Zi)} = θTZi. θ is estimated through maximum likeli-
hood estimator θ̂, which solves the estimating equation
n∑
i=1
Zi{Ai − expit(θTZi)} = 0.
Step 2. Calculate IPTW weight
We define pi1(θ) = P (Ai = 1|Zi, θ). The IPTW weight wi1(θ̂) = I(Ai = 1)/pi1(θ̂).
Step 3. Fit censoring model
We fit a Cox model for censoring where the time to censoring is outcome. Let X(t) =
{A,Z3, Z(t)}T , then the Cox model can be fit as λ1,i{t|Xi(t)} = λ01(t) exp{γT1 Xi(t)}.
Estimators for γ and Λ01(t) can be obtained by the maximum partial likelihood (PL)
estimator, γ̂ and the Breslow estimator, Λ̂01(t), respectively. The Breslow estimator









Step 4. Calculate IPCW weight
Let pci(γ, t) denote the probability that Ci is greater than t given {Xi(t), γ}. For
each patient at each time point, we calculate the IPCW weight wci (γ̂, t) = I(Ci ≥
80
t)/pci(γ̂, t).
Step 5. Find optimal β1
As described in Section 3.3, we used the OLS approach to minimize the variance of











ates, where g1(Zi) is a vector of basis function of Zi, e.g. g1(Zi) = (1, Z1,i, Z2,i, Z3,i).




















Step 6. Augmented estimator












Step 7. Estimate survival probability
S1(t) is estimated by Ŝ1(t) = e
−Λ̂1(t).
Step 8. Estimate restricted mean lifetime
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